Free CME from PeerView


Continuing Nursing Education (CNE) Activities

Amy Shapiro, MD
Credits: 1.0 CME / MOC / AAPA / IPCE
PVI, PeerView Institute for Medical Education
A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations

A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations

Start

A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations

Media: Enduring Material
Activity Release Date: March 13, 2024
Activity Expiration Date: March 12, 2025
Time to Complete Activity: 60 minutes

Activity Description

While significant progress has been made in the management of severe hemophilia A (HA), the needs of those with mild and moderate HA, including females, have long been sidelined. Until now. Join two experts as they explore the latest evidence with available pharmacologic treatment options, including FVIII mimetics, that are paving the way for equitable HA care. Through interactive case discussions, the experts will provide collaborative solutions for overcoming challenges related to identifying, engaging, and managing individuals with severe and non-severe HA to ensure no one is left behind in the pursuit of equitable care.

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, fellows, residents, and other healthcare professionals involved in the care of patients with hemophilia A.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Recognize unmet needs and barriers to equitable HA care, including among severe, nonsevere, and female HA populations
  • Summarize the evidence supporting established treatment options, including FVIII mimetic agents, with applications in diverse HA settings, including severe, nonsevere, and female HA populations
  • Develop individualized HA treatment plans with established therapeutics based on disease severity, inhibitor status, gender, and age, among other considerations
  • Employ principles of equitable, team-based, and participatory care when managing persons with HA, to ensure appropriate patient education, adherence counseling, and prompt management of disease- or treatment-related events

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Amy Shapiro, MD
Medical Director and CEO
Indiana Hemophilia and Thrombosis Center (IHTC)
Indianapolis, Indiana

Amy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.
Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.
Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.
Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.

Faculty/Planner
Maissaa Janbain, MD, MSCR
Associate Professor of Clinical Medicine
Director
Tulane University
Deming Department of Medicine
Section of Hematology & Medical Oncology - Louisiana Center for Bleeding & Clotting Disorders
New Orleans, Louisiana

Maissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.
Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/12/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations

Media: Enduring Material
Activity Release Date: March 13, 2024
Activity Expiration Date: March 12, 2025
Time to Complete Activity: 60 minutes

Activity Description

While significant progress has been made in the management of severe hemophilia A (HA), the needs of those with mild and moderate HA, including females, have long been sidelined. Until now. Join two experts as they explore the latest evidence with available pharmacologic treatment options, including FVIII mimetics, that are paving the way for equitable HA care. Through interactive case discussions, the experts will provide collaborative solutions for overcoming challenges related to identifying, engaging, and managing individuals with severe and non-severe HA to ensure no one is left behind in the pursuit of equitable care.

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, fellows, residents, and other healthcare professionals involved in the care of patients with hemophilia A.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Recognize unmet needs and barriers to equitable HA care, including among severe, nonsevere, and female HA populations
  • Summarize the evidence supporting established treatment options, including FVIII mimetic agents, with applications in diverse HA settings, including severe, nonsevere, and female HA populations
  • Develop individualized HA treatment plans with established therapeutics based on disease severity, inhibitor status, gender, and age, among other considerations
  • Employ principles of equitable, team-based, and participatory care when managing persons with HA, to ensure appropriate patient education, adherence counseling, and prompt management of disease- or treatment-related events

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Amy Shapiro, MD
Medical Director and CEO
Indiana Hemophilia and Thrombosis Center (IHTC)
Indianapolis, Indiana

Amy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.
Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.
Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.
Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.

Faculty/Planner
Maissaa Janbain, MD, MSCR
Associate Professor of Clinical Medicine
Director
Tulane University
Deming Department of Medicine
Section of Hematology & Medical Oncology - Louisiana Center for Bleeding & Clotting Disorders
New Orleans, Louisiana

Maissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.
Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/12/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

March 13, 2024
Hussein Tawbi, MD, PhD
Credits: 0.5 CME / MOC / NCPD / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options

Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options

Start

Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options

Media: Enduring Material

Activity Release Date: March 11, 2024

Activity Expiration Date: March 10, 2025

Time to Complete Activity: 30 minutes

Activity Description

Immunotherapy is now the centerpiece of modern, highly effective care for malignant melanoma. The most recent development in the immunotherapy revolution has centered on the validation of fixed-dose PD-1 and LAG-3 inhibitor combinations as an effective and safe frontline option for patients requiring treatment for advanced disease. This has raised a number of clinical questions related to the integration of PD-1/LAG-3 platforms into treatment plans (alongside other immune combinations) and the role of single-agent therapy.


This expert-led activity utilizes case-based teaching and short lectures to address these questions and provide guidance on incorporating the latest evidence on PD-1/LAG-3 therapy into practice, with the goal of illustrating the modern role of immune combinations in the frontline management of metastatic melanoma. The experts discuss how different baseline factors can inform treatment decisions made by the healthcare team, review the role of immunotherapy combinations in BRAF-mutant disease, and address practical aspects associated with the safe and effective delivery of dual checkpoint blockade with PD-1/LAG-3 platforms.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite updated guidelines and efficacy/safety evidence surrounding the use of newer immune-based approaches with PD-1/LAG-3 agents for unresectable and metastatic melanoma
  • Implement personalized treatment plans that include PD-1/LAG-3 combination therapies for unresectable and metastatic melanoma, including in BRAF-mutant or BRAF wild-type disease
  • Address practical aspects associated with newer dual checkpoint inhibition combinations, including irAE management and dosing, by working effectively in team-based care models

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Hussein Tawbi, MD, PhD

Deputy Chair and Professor

Department of Melanoma Medical Oncology

Co-Director, Andrew M. McDougall Brain Metastasis Clinic & Program

Melanoma Medical Oncology | Investigational Cancer Therapeutics

The University of Texas MD Anderson Cancer Center

Houston, Texas

Hussein Tawbi, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Boxer Capital, LLC; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche AG; Iovance Biotherapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Medicenna; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.

Grant/Research Support from Bristol Myers Squibb; Dragonfly Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation and RAPT Therapeutics. Research Support to Institution.

Faculty/Planner

Georgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS

Australian of the Year 2024

Co-Medical Director Melanoma Institute Australia

Professor of Melanoma Medical Oncology and Translational Research

Melanoma Institute Australia, The University of Sydney, and Royal North Shore & Mater Hospitals

Sydney, Australia

Georgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Agenus Inc.; Amgen Inc; Array Biopharma; AstraZeneca; Bayer AG; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Evaxion Biotech; Hexal AG (Sandoz Company); Highlight Therapeutics S.L.; IO Biotech; Immunocore; Innovent Biologics USA; Merck Sharpe & Dohme; Novartis; PHMR Ltd; Pierre Fabre; Regeneron Pharmaceuticals, Inc.; Scancell; and SkylineDX B.V.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008289-0000-24-035-H01-P

Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/10/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.


For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options

Media: Enduring Material

Activity Release Date: March 11, 2024

Activity Expiration Date: March 10, 2025

Time to Complete Activity: 30 minutes

Activity Description

Immunotherapy is now the centerpiece of modern, highly effective care for malignant melanoma. The most recent development in the immunotherapy revolution has centered on the validation of fixed-dose PD-1 and LAG-3 inhibitor combinations as an effective and safe frontline option for patients requiring treatment for advanced disease. This has raised a number of clinical questions related to the integration of PD-1/LAG-3 platforms into treatment plans (alongside other immune combinations) and the role of single-agent therapy.


This expert-led activity utilizes case-based teaching and short lectures to address these questions and provide guidance on incorporating the latest evidence on PD-1/LAG-3 therapy into practice, with the goal of illustrating the modern role of immune combinations in the frontline management of metastatic melanoma. The experts discuss how different baseline factors can inform treatment decisions made by the healthcare team, review the role of immunotherapy combinations in BRAF-mutant disease, and address practical aspects associated with the safe and effective delivery of dual checkpoint blockade with PD-1/LAG-3 platforms.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite updated guidelines and efficacy/safety evidence surrounding the use of newer immune-based approaches with PD-1/LAG-3 agents for unresectable and metastatic melanoma
  • Implement personalized treatment plans that include PD-1/LAG-3 combination therapies for unresectable and metastatic melanoma, including in BRAF-mutant or BRAF wild-type disease
  • Address practical aspects associated with newer dual checkpoint inhibition combinations, including irAE management and dosing, by working effectively in team-based care models

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Hussein Tawbi, MD, PhD

Deputy Chair and Professor

Department of Melanoma Medical Oncology

Co-Director, Andrew M. McDougall Brain Metastasis Clinic & Program

Melanoma Medical Oncology | Investigational Cancer Therapeutics

The University of Texas MD Anderson Cancer Center

Houston, Texas

Hussein Tawbi, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Boxer Capital, LLC; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche AG; Iovance Biotherapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Medicenna; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.

Grant/Research Support from Bristol Myers Squibb; Dragonfly Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation and RAPT Therapeutics. Research Support to Institution.

Faculty/Planner

Georgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS

Australian of the Year 2024

Co-Medical Director Melanoma Institute Australia

Professor of Melanoma Medical Oncology and Translational Research

Melanoma Institute Australia, The University of Sydney, and Royal North Shore & Mater Hospitals

Sydney, Australia

Georgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Agenus Inc.; Amgen Inc; Array Biopharma; AstraZeneca; Bayer AG; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Evaxion Biotech; Hexal AG (Sandoz Company); Highlight Therapeutics S.L.; IO Biotech; Immunocore; Innovent Biologics USA; Merck Sharpe & Dohme; Novartis; PHMR Ltd; Pierre Fabre; Regeneron Pharmaceuticals, Inc.; Scancell; and SkylineDX B.V.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008289-0000-24-035-H01-P

Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/10/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.


For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

March 11, 2024
Prof. Laurence Albiges, MD, PhD
Credits: 0.5 CME / MOC / NCPD / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic

Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic

Start

Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic

Media: Enduring Material

Activity Release Date: March 8, 2024

Activity Expiration Date: March 7, 2025

Time to Complete Activity: 30 minutes

Activity Description

In this video-based activity, an oncology expert discusses the role of subcutaneous (SC) immune checkpoint inhibitors in addressing unmet needs for the management of various solid tumors. Learn about evidence supporting SC administration of immune-oncology agents in different disease and treatment settings, and prepare to bring innovative formulations to the clinic.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, urologists, surgical oncologists, thoracic surgeons, NPs, PAs, nurses, pharmacists, and other healthcare professionals involved in the care of patients with cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Explain the potential of subcutaneous routes of administration of immune checkpoint inhibitors to address unmet needs in various cancer settings
  • Cite current evidence on the utilization of innovative routes of administration of immuno-oncology regimens when managing patients with cancer across different tumor and treatment settings
  • Apply team-based strategies to integrate innovative formulations of immune checkpoint inhibitors in real-world practice based on the latest clinical evidence, patient preferences, and other healthcare system factors

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Prof. Laurence Albiges, MD, PhD

Full Professor of Medical Oncology

Chair of Medical Oncology Department

Gustave Roussy Institute

Villejuif, France

Prof. Laurence Albiges, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Amgen Inc.; Astellas Pharma US, Inc.; Bristol Myers Squibb; Eisai Inc.; F. Hoffmann-La Roche Ltd; Ipsen Biopharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; and Pfizer Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008289-0000-24-038-H01-P

Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/7/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.


For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic

Media: Enduring Material

Activity Release Date: March 8, 2024

Activity Expiration Date: March 7, 2025

Time to Complete Activity: 30 minutes

Activity Description

In this video-based activity, an oncology expert discusses the role of subcutaneous (SC) immune checkpoint inhibitors in addressing unmet needs for the management of various solid tumors. Learn about evidence supporting SC administration of immune-oncology agents in different disease and treatment settings, and prepare to bring innovative formulations to the clinic.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, urologists, surgical oncologists, thoracic surgeons, NPs, PAs, nurses, pharmacists, and other healthcare professionals involved in the care of patients with cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Explain the potential of subcutaneous routes of administration of immune checkpoint inhibitors to address unmet needs in various cancer settings
  • Cite current evidence on the utilization of innovative routes of administration of immuno-oncology regimens when managing patients with cancer across different tumor and treatment settings
  • Apply team-based strategies to integrate innovative formulations of immune checkpoint inhibitors in real-world practice based on the latest clinical evidence, patient preferences, and other healthcare system factors

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Prof. Laurence Albiges, MD, PhD

Full Professor of Medical Oncology

Chair of Medical Oncology Department

Gustave Roussy Institute

Villejuif, France

Prof. Laurence Albiges, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Amgen Inc.; Astellas Pharma US, Inc.; Bristol Myers Squibb; Eisai Inc.; F. Hoffmann-La Roche Ltd; Ipsen Biopharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; and Pfizer Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008289-0000-24-038-H01-P

Type of Activity: Knowledge

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/7/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.


For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

March 08, 2024
Reshma L. Mahtani, DO
Credits: 1.0 CME / MOC / NCPD / IPCE
PVI, PeerView Institute for Medical Education
A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights

A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights

Start

 
 

A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights


 

Media: Enduring Material

    Activity Release Date: March 5, 2024

    Activity Expiration Date: March 4, 2025

    Time to Complete Activity: 60 minutes


 

Activity Description


 

HER2-targeting therapies are key components in the treatment of HER2-positive breast cancer. In this activity, a leading medical oncologist provides essential updates on the latest evidence and guideline recommendations for selecting and sequencing HER2-targeting therapies for HER2-positive metastatic breast cancer. In addition, real patient cases provide practical guidance for coordinating optimal breast cancer care across disciplines.


 

Target Audience


 

This activity has been designed to meet the educational needs of oncologists, pathologists, advanced practice providers, nurses, and other healthcare professionals involved in the care of patients with breast cancer.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Evaluate the characteristics, mechanisms of action, and latest safety and efficacy findings supporting the use of approved and emerging HER2-targeted therapies for HER2-positive MBC

  •    
  • Apply the latest evidence and guideline recommendations to optimally select and sequence HER2-targeting therapies for patients with HER2+ MBC, taking into account relevant treatment-, disease-, and patient-related factors

  •    
  • Collaborate with the members of the multidisciplinary and interprofessional team to develop individualized treatment plans for patients with HER2+ MBC, monitor and manage TRAEs, and engage patients as informed participants in their care

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Chair/Planner

    Reshma L. Mahtani, DO

    Chief of Breast Medical Oncology

    Miami Cancer Institute

    Baptist Health South Florida

    Member, Memorial Sloan Kettering Cancer Alliance

    Miami, Florida


 

Reshma L. Mahtani, DO, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Agendia; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Hologic, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.

    Grant/Research Support from AstraZeneca and Gilead Sciences, Inc.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


 
   
     
       
       
     
   
 
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.


 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/NCPD/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView



 
 

A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights


 

Media: Enduring Material

    Activity Release Date: March 5, 2024

    Activity Expiration Date: March 4, 2025

    Time to Complete Activity: 60 minutes


 

Activity Description


 

HER2-targeting therapies are key components in the treatment of HER2-positive breast cancer. In this activity, a leading medical oncologist provides essential updates on the latest evidence and guideline recommendations for selecting and sequencing HER2-targeting therapies for HER2-positive metastatic breast cancer. In addition, real patient cases provide practical guidance for coordinating optimal breast cancer care across disciplines.


 

Target Audience


 

This activity has been designed to meet the educational needs of oncologists, pathologists, advanced practice providers, nurses, and other healthcare professionals involved in the care of patients with breast cancer.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Evaluate the characteristics, mechanisms of action, and latest safety and efficacy findings supporting the use of approved and emerging HER2-targeted therapies for HER2-positive MBC

  •    
  • Apply the latest evidence and guideline recommendations to optimally select and sequence HER2-targeting therapies for patients with HER2+ MBC, taking into account relevant treatment-, disease-, and patient-related factors

  •    
  • Collaborate with the members of the multidisciplinary and interprofessional team to develop individualized treatment plans for patients with HER2+ MBC, monitor and manage TRAEs, and engage patients as informed participants in their care

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Chair/Planner

    Reshma L. Mahtani, DO

    Chief of Breast Medical Oncology

    Miami Cancer Institute

    Baptist Health South Florida

    Member, Memorial Sloan Kettering Cancer Alliance

    Miami, Florida


 

Reshma L. Mahtani, DO, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Agendia; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Hologic, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.

    Grant/Research Support from AstraZeneca and Gilead Sciences, Inc.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


 
   
     
       
       
     
   
 
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.


 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/NCPD/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView


March 05, 2024
Alok A. Khorana, MD, FACP, FASCO
Credits: 0.75 CME / MOC / AAPA / IPCE
PVI, PeerView Institute for Medical Education
REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism

REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism

Start

REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism

Media: Enduring Material

Activity Release Date: March 1, 2024

Activity Expiration Date: February 28, 2025

Time to Complete Activity: 45 minutes

Activity Description

Venous thromboembolism (VTE), is a significant complication in cancer patients and a leading cause of mortality in this setting. Despite the availability of numerous guidelines and resources for cancer-associated VTE prevention and treatment, the uneven implementation of effective anticoagulation remains a barrier to highly effective management.


In this PeerView virtual activity, a leading expert on cancer-associated VTE will provide clinical insights and case-based guidance on current prevention and treatment strategies for cancer-associated VTE. Throughout, the faculty will address modern prophylactic and therapeutic anticoagulation options, underscore the importance of risk assessment and timely management, and offer insights into the selection of anticoagulants. Additionally, the expert will highlight the importance of an interprofessional team-based approach, aligned with shared decision-making, when caring for patients at risk of cancer-associated VTE.

Target Audience

This activity has been designed to meet the educational needs of oncologists, NPs, PAs, and other care team clinicians involved in the prevention and management of cancer-associated VTE.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite recognized thromboembolic risk factors, guideline recommendations for modern risk assessment, and current evidence supporting modern anticoagulation strategies for cancer-associated VTE
  • Implement risk-adapted prophylaxis and treatment strategies for cancer-associated VTE while employing the principles of equitable, team-based, and participatory care
  • Manage practical aspects of VTE management in the cancer setting, including safe dosing and delivery of therapy, and provision of patient counseling on elevated VTE risks, adherence to treatment plans, and the risks/benefits of anticoagulation

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Alok A. Khorana, MD, FACP, FASCO

Sondra and Stephen Hardis Endowed Chair in Oncology Research

Vice-Chair, Taussig Cancer Center

Director, GI Malignancies Program

Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University

Cleveland, Ohio

Alok A. Khorana, MD, FACP, FASCO, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Anthos Therapeutics; Bayer Corporation; Bristol Myers Squibb; Pfizer; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 2/28/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism

Media: Enduring Material

Activity Release Date: March 1, 2024

Activity Expiration Date: February 28, 2025

Time to Complete Activity: 45 minutes

Activity Description

Venous thromboembolism (VTE), is a significant complication in cancer patients and a leading cause of mortality in this setting. Despite the availability of numerous guidelines and resources for cancer-associated VTE prevention and treatment, the uneven implementation of effective anticoagulation remains a barrier to highly effective management.


In this PeerView virtual activity, a leading expert on cancer-associated VTE will provide clinical insights and case-based guidance on current prevention and treatment strategies for cancer-associated VTE. Throughout, the faculty will address modern prophylactic and therapeutic anticoagulation options, underscore the importance of risk assessment and timely management, and offer insights into the selection of anticoagulants. Additionally, the expert will highlight the importance of an interprofessional team-based approach, aligned with shared decision-making, when caring for patients at risk of cancer-associated VTE.

Target Audience

This activity has been designed to meet the educational needs of oncologists, NPs, PAs, and other care team clinicians involved in the prevention and management of cancer-associated VTE.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite recognized thromboembolic risk factors, guideline recommendations for modern risk assessment, and current evidence supporting modern anticoagulation strategies for cancer-associated VTE
  • Implement risk-adapted prophylaxis and treatment strategies for cancer-associated VTE while employing the principles of equitable, team-based, and participatory care
  • Manage practical aspects of VTE management in the cancer setting, including safe dosing and delivery of therapy, and provision of patient counseling on elevated VTE risks, adherence to treatment plans, and the risks/benefits of anticoagulation

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Alok A. Khorana, MD, FACP, FASCO

Sondra and Stephen Hardis Endowed Chair in Oncology Research

Vice-Chair, Taussig Cancer Center

Director, GI Malignancies Program

Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University

Cleveland, Ohio

Alok A. Khorana, MD, FACP, FASCO, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Anthos Therapeutics; Bayer Corporation; Bristol Myers Squibb; Pfizer; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 2/28/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

March 01, 2024
Benjamin Levy, MD
Credits: 1.0 CME / MOC / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer

Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer

Start

Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer

Media: Enduring Material
Activity Release Date: February 24, 2024
Activity Expiration Date: March 23, 2025
Time to Complete Activity: 60 minutes

Activity Description

Antibody-drug conjugates (ADCs) represent an exciting frontier in the realm of precision lung cancer care, bringing hope to patients with limited treatment options. The promise of these agents is now transitioning from research settings to real-world practice, but many questions remain to be answered by ongoing studies. In addition to the first HER2-targeting ADC approved for HER2-mutated NSCLC, various other potent ADCs, such as those targeting HER3, TROP2, B7-H3, among many others, are showing promising activity in clinical trials, either as monotherapies or as integral parts of combinations, spanning different settings and patient populations.

This unique educational activity, based on a recent live symposium, features entertaining quiz-based Peer Pressure Challenges during which top experts are put on the spot to compete against each other and test their knowledge about ADCs. These game show segments are combined with related mini-lectures and open discussion forums to review key concepts related to the ADCs, analyze the latest evidence, examine unique nuances of using these therapies in real-world practice, and explore the challenging issues and burning questions about how to maximize the potential of ADCs in lung cancer.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, and other multidisciplinary and interprofessional healthcare providers involved in the care of patients with lung cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the clinical importance and biologic rationale for the use of different ADC-based approaches in lung cancer.
  • Summarize the characteristics, mechanisms of action, and safety and efficacy profiles of various ADCs in lung cancer.
  • Integrate ADCs into treatment plans of carefully selected patients with lung cancer.
  • Follow best practices to identify and manage treatment-related adverse events in patients with lung cancer receiving ADC-based therapies with the entire care team to improve outcomes and quality of life.

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Benjamin Levy, MD
Associate Professor, Johns Hopkins School of Medicine
Clinical Director, Johns Hopkins Sidney Kimmel Cancer Center (SKCC) at Sibley Memorial Hospital
Medical Director, Thoracic Oncology Program, SKCC at Sibley
Washington, District of Columbia

Benjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.

Faculty/Planner
Marina Chiara Garassino, MD
Professor of Medicine
Director, Thoracic Oncology Program
University of Chicago Medicine
Hematology-Oncology
Chicago, Illinois

Marina Chiara Garassino, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; OSE Immunotherapeutics; Pfizer; Regeneron Pharmaceuticals Inc.; Seattle Genetics, Inc.; and Takeda Pharmaceutical Company Ltd.
Grant/Research Support from Research funding to institution for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine, Inc.; GlaxoSmithKline; Lilly; Merck Sharp & Dohme Corp.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Spectrum Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Ltd.
Speaker for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Ltd/Mirati Therapeutics, Inc.

Faculty/Planner
Stephen V. Liu, MD
Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, District of Columbia

Stephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.
Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; Puma Biotechnology, Inc.; RAPT Therapeutics; and Turning Point Therapeutics, Inc.

Faculty/Planner
Zosia Piotrowska, MD
Assistant Professor of Medicine, Harvard Medical School
Assistant in Medicine, Massachusetts General Hospital
Boston, Massachusetts

Zosia Piotrowska, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer Corporation; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Sanofi; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from AbbVie Inc.; AstraZeneca; Blueprint Medicines Corporation; Cullinan Oncology, Inc; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and Tesaro, Inc./GlaxoSmithKline.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/23/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer

Media: Enduring Material
Activity Release Date: February 24, 2024
Activity Expiration Date: March 23, 2025
Time to Complete Activity: 60 minutes

Activity Description

Antibody-drug conjugates (ADCs) represent an exciting frontier in the realm of precision lung cancer care, bringing hope to patients with limited treatment options. The promise of these agents is now transitioning from research settings to real-world practice, but many questions remain to be answered by ongoing studies. In addition to the first HER2-targeting ADC approved for HER2-mutated NSCLC, various other potent ADCs, such as those targeting HER3, TROP2, B7-H3, among many others, are showing promising activity in clinical trials, either as monotherapies or as integral parts of combinations, spanning different settings and patient populations.

This unique educational activity, based on a recent live symposium, features entertaining quiz-based Peer Pressure Challenges during which top experts are put on the spot to compete against each other and test their knowledge about ADCs. These game show segments are combined with related mini-lectures and open discussion forums to review key concepts related to the ADCs, analyze the latest evidence, examine unique nuances of using these therapies in real-world practice, and explore the challenging issues and burning questions about how to maximize the potential of ADCs in lung cancer.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, and other multidisciplinary and interprofessional healthcare providers involved in the care of patients with lung cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the clinical importance and biologic rationale for the use of different ADC-based approaches in lung cancer.
  • Summarize the characteristics, mechanisms of action, and safety and efficacy profiles of various ADCs in lung cancer.
  • Integrate ADCs into treatment plans of carefully selected patients with lung cancer.
  • Follow best practices to identify and manage treatment-related adverse events in patients with lung cancer receiving ADC-based therapies with the entire care team to improve outcomes and quality of life.

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Benjamin Levy, MD
Associate Professor, Johns Hopkins School of Medicine
Clinical Director, Johns Hopkins Sidney Kimmel Cancer Center (SKCC) at Sibley Memorial Hospital
Medical Director, Thoracic Oncology Program, SKCC at Sibley
Washington, District of Columbia

Benjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.

Faculty/Planner
Marina Chiara Garassino, MD
Professor of Medicine
Director, Thoracic Oncology Program
University of Chicago Medicine
Hematology-Oncology
Chicago, Illinois

Marina Chiara Garassino, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; OSE Immunotherapeutics; Pfizer; Regeneron Pharmaceuticals Inc.; Seattle Genetics, Inc.; and Takeda Pharmaceutical Company Ltd.
Grant/Research Support from Research funding to institution for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine, Inc.; GlaxoSmithKline; Lilly; Merck Sharp & Dohme Corp.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Spectrum Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Ltd.
Speaker for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Ltd/Mirati Therapeutics, Inc.

Faculty/Planner
Stephen V. Liu, MD
Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, District of Columbia

Stephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.
Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; Puma Biotechnology, Inc.; RAPT Therapeutics; and Turning Point Therapeutics, Inc.

Faculty/Planner
Zosia Piotrowska, MD
Assistant Professor of Medicine, Harvard Medical School
Assistant in Medicine, Massachusetts General Hospital
Boston, Massachusetts

Zosia Piotrowska, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer Corporation; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Sanofi; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from AbbVie Inc.; AstraZeneca; Blueprint Medicines Corporation; Cullinan Oncology, Inc; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and Tesaro, Inc./GlaxoSmithKline.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/23/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

February 24, 2024
Taofeek K. Owonikoko, MD, PhD
Credits: 1.0 CME / MOC / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

Start

Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

Media: Enduring Material

Activity Release Date: February 24, 2024

Activity Expiration Date: March 23, 2025

Time to Complete Activity: 60 minutes

Activity Description

In recent years, there have been notable advances in the treatment of small-cell lung cancer (SCLC). Several new options have now become guideline-recommended standards of care. Despite these advancements, the prognosis for SCLC remains poor. This justifies efforts to optimize and expand the use of approved treatments and explore novel therapies with different mechanisms of action. Several potential therapeutic strategies are currently under examination in clinical trials that will hopefully lead to a further expansion of the SCLC treatment arsenal.


In this PeerView educational activity, based on a recent live symposium, experts discuss the latest evidence, ongoing trials, clinical cases, and challenging questions to take a deeper dive into the nuances of how to optimally integrate the latest therapeutic advances into clinical practice. The faculty panel provides evidence-based and practical guidance to help the lung cancer care team better understand the current and evolving treatment arsenal for SCLC and improve the care and outcomes of patients with SCLC.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, and other clinicians involved in the management of SCLC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Analyze the role and use of current and emerging therapies for SCLC, and the evidence that supports their use
  • Incorporate current standard-of-care therapies into individualized treatment plans for patients with SCLC based on the latest evidence, guideline recommendations, and patient needs and preferences
  • Recommend enrollment in clinical trials to eligible patients who could benefit from the current and emerging therapies
  • Implement multidisciplinary/interprofessional strategies and shared decision-making to ensure optimal care, including effective management of AEs, throughout the disease continuum for each patient with SCLC

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Taofeek K. Owonikoko, MD, PhD

Executive Director, Marlene and Stewart Greenebaum Comprehensive Cancer Center

Marlene and Stewart Greenebaum Professor in Oncology

Senior Associate Dean of Cancer Programs, University of Maryland School of Medicine

Associate Vice President for Cancer Programs, University of Maryland, Baltimore

Chief of Service, University of Maryland Medical Center

Baltimore, Maryland

Taofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.; GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.

Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics, Inc.; and Y-mAbs Therapeutics, Inc.

Faculty/Planner

Anne Chiang, MD, PhD, FASCO

Associate Professor of Medicine

Associate Yale Cancer Center Director, Clinical Initiatives

Yale University School of Medicine

New Haven, Connecticut

Anne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.

Grant/Research Support from AbbVie, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.

Faculty/Planner

Jared Weiss, MD

Professor of Medicine

Section Chief of Thoracic and Head/Neck Oncology

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina

Jared Weiss, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly; Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.

Grant/Research Support from G1 Therapeutics, Inc.; Inspirna, Inc.; and Lilly.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/23/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

Media: Enduring Material

Activity Release Date: February 24, 2024

Activity Expiration Date: March 23, 2025

Time to Complete Activity: 60 minutes

Activity Description

In recent years, there have been notable advances in the treatment of small-cell lung cancer (SCLC). Several new options have now become guideline-recommended standards of care. Despite these advancements, the prognosis for SCLC remains poor. This justifies efforts to optimize and expand the use of approved treatments and explore novel therapies with different mechanisms of action. Several potential therapeutic strategies are currently under examination in clinical trials that will hopefully lead to a further expansion of the SCLC treatment arsenal.


In this PeerView educational activity, based on a recent live symposium, experts discuss the latest evidence, ongoing trials, clinical cases, and challenging questions to take a deeper dive into the nuances of how to optimally integrate the latest therapeutic advances into clinical practice. The faculty panel provides evidence-based and practical guidance to help the lung cancer care team better understand the current and evolving treatment arsenal for SCLC and improve the care and outcomes of patients with SCLC.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, and other clinicians involved in the management of SCLC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Analyze the role and use of current and emerging therapies for SCLC, and the evidence that supports their use
  • Incorporate current standard-of-care therapies into individualized treatment plans for patients with SCLC based on the latest evidence, guideline recommendations, and patient needs and preferences
  • Recommend enrollment in clinical trials to eligible patients who could benefit from the current and emerging therapies
  • Implement multidisciplinary/interprofessional strategies and shared decision-making to ensure optimal care, including effective management of AEs, throughout the disease continuum for each patient with SCLC

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Taofeek K. Owonikoko, MD, PhD

Executive Director, Marlene and Stewart Greenebaum Comprehensive Cancer Center

Marlene and Stewart Greenebaum Professor in Oncology

Senior Associate Dean of Cancer Programs, University of Maryland School of Medicine

Associate Vice President for Cancer Programs, University of Maryland, Baltimore

Chief of Service, University of Maryland Medical Center

Baltimore, Maryland

Taofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.; GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.

Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics, Inc.; and Y-mAbs Therapeutics, Inc.

Faculty/Planner

Anne Chiang, MD, PhD, FASCO

Associate Professor of Medicine

Associate Yale Cancer Center Director, Clinical Initiatives

Yale University School of Medicine

New Haven, Connecticut

Anne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.

Grant/Research Support from AbbVie, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.

Faculty/Planner

Jared Weiss, MD

Professor of Medicine

Section Chief of Thoracic and Head/Neck Oncology

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina

Jared Weiss, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly; Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.

Grant/Research Support from G1 Therapeutics, Inc.; Inspirna, Inc.; and Lilly.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/23/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

February 24, 2024
Credits: 1.0 CME / MOC / AAPA / IPCE
Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon EGFR Mutations: How to Navigate the Expanding Options and Increasing Complexity

Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon EGFR Mutations: How to Navigate the Expanding Options and Increasing Complexity

Start

Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon EGFR Mutations: How to Navigate the Expanding Options and Increasing Complexity

Media: Enduring Material

Activity Release Date: February 21, 2024

Activity Expiration Date: March 20, 2025

Time to Complete Activity: 60 minutes

Activity Description

Multiple EGFR-targeted therapies have become available for patients with NSCLC harboring common and uncommon EGFR mutations, and novel options and combinations with practice-changing potential have shown great promise in clinical trials. How can healthcare providers make sense of the increasing complexity in the evidence base and best select and sequence the current and emerging therapy options?


In this PeerView educational activity, based on a recent live symposium, expert panelists provide guidance on appropriate biomarker testing, discuss the expanding landscape of targeted therapy options, and explore the nuances of making precision decisions for patients with EGFR-mutated NSCLC.

Target Audience

This activity has been designed to meet the educational needs of thoracic oncologists, medical oncologists, advanced practice clinicians, and other clinicians involved in the management of patients with lung cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Explain the evolving role of EGFR mutations and co-occurring genomic alterations in guiding decision-making and treatment selection for patients with NSCLC
  • Apply broad NGS-based testing to identify therapeutically actionable alterations, including EGFR mutations, and potential resistance mechanisms
  • Integrate biomarker findings, clinical trial evidence, and shared decision-making strategies to personalize treatment planning in EGFRm NSCLC settings
  • Construct team-based strategies to ensure individualized care throughout the course of treatment, including patient/caregiver education and engagement, and optimal approaches to facilitate shared decision-making in EGFRm NSCLC

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Joshua Sabari, MD

Assistant Professor of Medicine

NYU Langone Health

Perlmutter Cancer Center

New York, New York

Joshua Sabari, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited.

Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron Pharmaceuticals Inc.

Faculty/Planner

Jyoti D. Patel, MD

Professor of Medicine

Medical Director for Thoracic Oncology

Assistant Director for Clinical Research

Lurie Cancer Center

Associate Vice Chair of Clinical Research

Department of Medicine

Northwestern University, Feinberg School of Medicine

Chicago, Illinois

Jyoti D. Patel, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; AstraZeneca; Blueprint Medicines Corporation; Daiichi Sankyo, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Sanofi; and Takeda Pharmaceutical Company Limited.

Other Financial or Material Support for Travel from Daiichi Sankyo, Inc. and Tempus.

Faculty/Planner

Alexander I. Spira, MD, PhD, FACP

Co Director Virginia Cancer Specialists Research Institute

Director, NEXT Oncology Virginia

Co Chair, US Oncology Thoracic Research Program

Fairfax, Virginia

Alexander I. Spira, MD, PhD, FACP, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Amgen Inc.; Array BioPharma Inc.; AstraZeneca/ MedImmune; Black Diamond Therapeutics; Blueprint Medicines Corporation; Bristol Myers Squibb; Daiichi Sankyo, Inc./AstraZeneca; Incyte; Gritstone bio, Inc.; Janssen Research & Development; Jazz Pharmaceuticals, Inc.; Lily; Merck & Co., Inc.; Mersana Therapeutics; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.

Grant/Research Support from ADC Therapeutics SA; AbbVie Inc.; Alkermes; Amgen Inc.; Arch Therapeutics, Inc.; ArriVent Biopharma; Astellas Pharma US, Inc.; Astex Pharmaceuticals; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines Corporation; Bluprint Oncology; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Gritstone bio, Inc.; Ignyta Inc; Incyte; Janssen Oncology; LAM Therapeutics, Inc.; Loxo Oncology; MacroGenics, Inc.; Medikine, Inc; MedImmune; Mersana Therapeutics; Mirati Therapeutics, Inc.; NALO Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Plexxikon; Regeneron Pharmaceuticals Inc.; Revolution Medicines, Inc.; Rubius Therapeutics; Scorpion Therapeutics; Synthekine; and Takeda Pharmaceutical Company Limited.

Honoraria from Amgen Inc.; AstraZeneca/ MedImmune; Bayer; Bristol Myers Sqiubb; CytomX Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.

Stock Shareholder in Lilly.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/20/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon EGFR Mutations: How to Navigate the Expanding Options and Increasing Complexity

Media: Enduring Material

Activity Release Date: February 21, 2024

Activity Expiration Date: March 20, 2025

Time to Complete Activity: 60 minutes

Activity Description

Multiple EGFR-targeted therapies have become available for patients with NSCLC harboring common and uncommon EGFR mutations, and novel options and combinations with practice-changing potential have shown great promise in clinical trials. How can healthcare providers make sense of the increasing complexity in the evidence base and best select and sequence the current and emerging therapy options?


In this PeerView educational activity, based on a recent live symposium, expert panelists provide guidance on appropriate biomarker testing, discuss the expanding landscape of targeted therapy options, and explore the nuances of making precision decisions for patients with EGFR-mutated NSCLC.

Target Audience

This activity has been designed to meet the educational needs of thoracic oncologists, medical oncologists, advanced practice clinicians, and other clinicians involved in the management of patients with lung cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Explain the evolving role of EGFR mutations and co-occurring genomic alterations in guiding decision-making and treatment selection for patients with NSCLC
  • Apply broad NGS-based testing to identify therapeutically actionable alterations, including EGFR mutations, and potential resistance mechanisms
  • Integrate biomarker findings, clinical trial evidence, and shared decision-making strategies to personalize treatment planning in EGFRm NSCLC settings
  • Construct team-based strategies to ensure individualized care throughout the course of treatment, including patient/caregiver education and engagement, and optimal approaches to facilitate shared decision-making in EGFRm NSCLC

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Joshua Sabari, MD

Assistant Professor of Medicine

NYU Langone Health

Perlmutter Cancer Center

New York, New York

Joshua Sabari, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited.

Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron Pharmaceuticals Inc.

Faculty/Planner

Jyoti D. Patel, MD

Professor of Medicine

Medical Director for Thoracic Oncology

Assistant Director for Clinical Research

Lurie Cancer Center

Associate Vice Chair of Clinical Research

Department of Medicine

Northwestern University, Feinberg School of Medicine

Chicago, Illinois

Jyoti D. Patel, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; AstraZeneca; Blueprint Medicines Corporation; Daiichi Sankyo, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Sanofi; and Takeda Pharmaceutical Company Limited.

Other Financial or Material Support for Travel from Daiichi Sankyo, Inc. and Tempus.

Faculty/Planner

Alexander I. Spira, MD, PhD, FACP

Co Director Virginia Cancer Specialists Research Institute

Director, NEXT Oncology Virginia

Co Chair, US Oncology Thoracic Research Program

Fairfax, Virginia

Alexander I. Spira, MD, PhD, FACP, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Amgen Inc.; Array BioPharma Inc.; AstraZeneca/ MedImmune; Black Diamond Therapeutics; Blueprint Medicines Corporation; Bristol Myers Squibb; Daiichi Sankyo, Inc./AstraZeneca; Incyte; Gritstone bio, Inc.; Janssen Research & Development; Jazz Pharmaceuticals, Inc.; Lily; Merck & Co., Inc.; Mersana Therapeutics; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.

Grant/Research Support from ADC Therapeutics SA; AbbVie Inc.; Alkermes; Amgen Inc.; Arch Therapeutics, Inc.; ArriVent Biopharma; Astellas Pharma US, Inc.; Astex Pharmaceuticals; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines Corporation; Bluprint Oncology; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Gritstone bio, Inc.; Ignyta Inc; Incyte; Janssen Oncology; LAM Therapeutics, Inc.; Loxo Oncology; MacroGenics, Inc.; Medikine, Inc; MedImmune; Mersana Therapeutics; Mirati Therapeutics, Inc.; NALO Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Plexxikon; Regeneron Pharmaceuticals Inc.; Revolution Medicines, Inc.; Rubius Therapeutics; Scorpion Therapeutics; Synthekine; and Takeda Pharmaceutical Company Limited.

Honoraria from Amgen Inc.; AstraZeneca/ MedImmune; Bayer; Bristol Myers Sqiubb; CytomX Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.

Stock Shareholder in Lilly.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/20/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.


A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.


If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

February 21, 2024
Erin X. Barrett (Wei), MD/David Rosmarin, MD
Credits: 1.0 CME / MOC / NCPD / AAPA
PVI, PeerView Institute for Medical Education
Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care

Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care

Start

       
       

Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care


       

Media: Enduring Material
Activity Release Date: February 7, 2024
Activity Expiration Date: February 6, 2025
Time to Complete Activity: 60 minutes

Activity Description

Bullous pemphigoid (BP) is a rare autoimmune subepidermal blistering disease characterized by large, tense blisters in the skin preceded by urticarial plaques and pruritus. It occurs most frequently in elderly patients, with risk rising exponentially after the age of 80. Diagnosis is often missed or delayed, partly due to it being a rare disorder, and partly due to atypical presentations or similarities with other skin conditions.

Although management guidelines have been updated there is still a lack of consensus on optimal treatment regimens and duration. Systemic corticosteroids and other immunosuppressive agents carry risks of adverse events; thus, targeted agents that are already approved for other diseases are under study for their utility in BP.

In order to help dermatologists and other clinicians treating patients with BP remain updated on advances in treatment, PeerView has prepared this discussion between two expert dermatologists. Learners will hear about the impact of BP on patient quality of life and how to differentiate BP from other skin conditions, as well as how to treat patients using the latest guidelines and targeted therapy.

Target Audience

This activity has been designed to meet the educational needs of dermatologists, dermatology advanced practice providers, and other clinicians who care for patients with bullous pemphigoid.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify and differentiate bullous pemphigoid (BP) from other skin conditions that can present similarly, based on current guidelines and expert recommendations
  • Discuss the impact of BP on elderly patients with regard to morbidity/mortality and quality of life, particularly for those with several comorbidities
  • Select and monitor treatment for patients with BP according to updated guidelines
  • Explain the rationale to improve outcomes for patients with BP through the use of targeted therapy

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Erin X. Barrett (Wei), MD
Associate Professor of Dermatology
University of Nebraska Medical Center/Nebraska Medicine
Co-Director of the Bullous Disease Clinic
Director of Clinical Trials
Director of Inpatient Dermatology Services
Director of the Skin of Color/Ethnic Skin Dermatology Clinic
Omaha, Nebraska

Erin X. Barrett (Wei), MD, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
David Rosmarin, MD
Chair, Kampen-Norins Scholar
Indiana University
Indianapolis, Indiana

David Rosmarin, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Abcuro, Inc; AltruBio, Inc.; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Meyers Squibb; Celgene Corporation; Concert Pharmaceuticals, Inc.; CSL; Dermavant Sciences, Inc.; Dermira, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Kyowa Kirin Co., Ltd.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Recludix; Revolo Biotherapeutics; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries, Ltd.; UCB; and Viela Bio, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermira, Inc.; Galderma S.A. ; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.
Speaker for AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


                   
                       
                       
                   
               
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement


                   
                       
                       
                   
               
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Physician Assistants


                   
                       
                       
                   
               
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/6/2025. PAs should only claim credit commensurate with the extent of their participation.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


       

Copyright © 2000-2024, PeerView


   

       
       

Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care


       

Media: Enduring Material
Activity Release Date: February 7, 2024
Activity Expiration Date: February 6, 2025
Time to Complete Activity: 60 minutes

Activity Description

Bullous pemphigoid (BP) is a rare autoimmune subepidermal blistering disease characterized by large, tense blisters in the skin preceded by urticarial plaques and pruritus. It occurs most frequently in elderly patients, with risk rising exponentially after the age of 80. Diagnosis is often missed or delayed, partly due to it being a rare disorder, and partly due to atypical presentations or similarities with other skin conditions.

Although management guidelines have been updated there is still a lack of consensus on optimal treatment regimens and duration. Systemic corticosteroids and other immunosuppressive agents carry risks of adverse events; thus, targeted agents that are already approved for other diseases are under study for their utility in BP.

In order to help dermatologists and other clinicians treating patients with BP remain updated on advances in treatment, PeerView has prepared this discussion between two expert dermatologists. Learners will hear about the impact of BP on patient quality of life and how to differentiate BP from other skin conditions, as well as how to treat patients using the latest guidelines and targeted therapy.

Target Audience

This activity has been designed to meet the educational needs of dermatologists, dermatology advanced practice providers, and other clinicians who care for patients with bullous pemphigoid.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify and differentiate bullous pemphigoid (BP) from other skin conditions that can present similarly, based on current guidelines and expert recommendations
  • Discuss the impact of BP on elderly patients with regard to morbidity/mortality and quality of life, particularly for those with several comorbidities
  • Select and monitor treatment for patients with BP according to updated guidelines
  • Explain the rationale to improve outcomes for patients with BP through the use of targeted therapy

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Erin X. Barrett (Wei), MD
Associate Professor of Dermatology
University of Nebraska Medical Center/Nebraska Medicine
Co-Director of the Bullous Disease Clinic
Director of Clinical Trials
Director of Inpatient Dermatology Services
Director of the Skin of Color/Ethnic Skin Dermatology Clinic
Omaha, Nebraska

Erin X. Barrett (Wei), MD, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
David Rosmarin, MD
Chair, Kampen-Norins Scholar
Indiana University
Indianapolis, Indiana

David Rosmarin, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Abcuro, Inc; AltruBio, Inc.; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Meyers Squibb; Celgene Corporation; Concert Pharmaceuticals, Inc.; CSL; Dermavant Sciences, Inc.; Dermira, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Kyowa Kirin Co., Ltd.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Recludix; Revolo Biotherapeutics; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries, Ltd.; UCB; and Viela Bio, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermira, Inc.; Galderma S.A. ; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.
Speaker for AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


                   
                       
                       
                   
               
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement


                   
                       
                       
                   
               
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Physician Assistants


                   
                       
                       
                   
               
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/6/2025. PAs should only claim credit commensurate with the extent of their participation.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


       

Copyright © 2000-2024, PeerView


   
February 07, 2024
Lipika Goyal, MD, MPhil/Riad Salem, MD, MBA
Credits: 0.75 CME / MOC / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum

Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum

Start

 
 

Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum


 

Media: Enduring Material

    Activity Release Date: January 27, 2024

    Activity Expiration Date: February 26, 2025

    Time to Complete Activity: 45 minutes


 

Activity Description


 

Developments in treatment options for hepatocellular carcinoma (HCC), namely immune-based strategies, have enhanced outcomes across the disease continuum. To effectively integrate these modern regimens into practice, close collaboration among interventional radiologists (IR), medical oncologists, and the wider care team are critical. In this Clinical Consults activity, the expert faculty panel discuss patient scenarios illustrating real-world applications of current and emerging data and provide guidance on topics such as selecting and sequencing treatment over the course of disease, delivering personalized care when integrating immunotherapy platforms, and anticipating and managing safety/toxicity considerations.

   

    This activity unravels the latest data on innovative immunotherapy and locoregional therapy combinations in intermediate-stage disease and the transition to systemic therapy in advanced disease. Join today to learn what the experts have to say for synergizing success in HCC!


 

Target Audience


 

This activity has been designed to meet the educational needs of interventional radiologists, medical oncologists, advanced practice clinicians, and other healthcare professionals involved in the management of HCC.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Discuss the latest safety/efficacy evidence and guideline recommendations supporting clinical applications of immunotherapy regimens for the management of early-, intermediate-, and advanced-stage HCC

  •    
  • Formulate personalized treatment plans with immunotherapy platforms for the management of HCC based on current and emerging clinical evidence, guideline recommendations, and expert guidance

  •    
  • Apply team-based strategies to address practical aspects of care when integrating immunotherapy platforms, including managing immune-related adverse events, dosing considerations, care coordination across specialties, and patient/caregiver education

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Co-Chair/Planner

    Lipika Goyal, MD, MPhil

    Director of Gastrointestinal Oncology

    Associate Professor of Medicine

    Division of Oncology

    Stanford School of Medicine

    Palo Alto, California


 

Lipika Goyal, MD, MPhil, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Alentis Therapeutics AG; Basilea Pharmaceutica; Black Diamond Therapeutics, Inc.; Blueprint Medicines Corporation; Eisai Inc./H3Biomedicine; Exelixis, Inc.; Genentech, Inc.; Incyte Corporation; Kinnate Biopharma Inc.; Merck & Co., Inc.; QED Therapeutics; Relay Therapeutics; Servier Pharmaceuticals; Sirtex Medical Ltd; Surface Oncology; Taiho Oncology, Inc.; and TransThera Biosciences.

    Data Safety Monitoring Board for AstraZeneca.

 


 

Co-Chair/Planner

    Riad Salem, MD, MBA

    Professor of Radiology, Medicine, and Surgery

    Chief, Section of Vascular and Interventional Radiology

    Vice-Chairman, Image-Guided Therapy

    Department of Radiology

    Northwestern University Feinberg School of Medicine

    Chicago, Illinois


 

Riad Salem, MD, MBA, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AstraZeneca; Bard Pharmaceuticals; Boston Scientific Corporation; Cook Medical; Eisai Inc./Merck & Co., Inc.; and Genentech, Inc.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by an independent educational grant from AstraZeneca.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 2/26/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView



 
 

Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum


 

Media: Enduring Material

    Activity Release Date: January 27, 2024

    Activity Expiration Date: February 26, 2025

    Time to Complete Activity: 45 minutes


 

Activity Description


 

Developments in treatment options for hepatocellular carcinoma (HCC), namely immune-based strategies, have enhanced outcomes across the disease continuum. To effectively integrate these modern regimens into practice, close collaboration among interventional radiologists (IR), medical oncologists, and the wider care team are critical. In this Clinical Consults activity, the expert faculty panel discuss patient scenarios illustrating real-world applications of current and emerging data and provide guidance on topics such as selecting and sequencing treatment over the course of disease, delivering personalized care when integrating immunotherapy platforms, and anticipating and managing safety/toxicity considerations.

   

    This activity unravels the latest data on innovative immunotherapy and locoregional therapy combinations in intermediate-stage disease and the transition to systemic therapy in advanced disease. Join today to learn what the experts have to say for synergizing success in HCC!


 

Target Audience


 

This activity has been designed to meet the educational needs of interventional radiologists, medical oncologists, advanced practice clinicians, and other healthcare professionals involved in the management of HCC.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Discuss the latest safety/efficacy evidence and guideline recommendations supporting clinical applications of immunotherapy regimens for the management of early-, intermediate-, and advanced-stage HCC

  •    
  • Formulate personalized treatment plans with immunotherapy platforms for the management of HCC based on current and emerging clinical evidence, guideline recommendations, and expert guidance

  •    
  • Apply team-based strategies to address practical aspects of care when integrating immunotherapy platforms, including managing immune-related adverse events, dosing considerations, care coordination across specialties, and patient/caregiver education

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Co-Chair/Planner

    Lipika Goyal, MD, MPhil

    Director of Gastrointestinal Oncology

    Associate Professor of Medicine

    Division of Oncology

    Stanford School of Medicine

    Palo Alto, California


 

Lipika Goyal, MD, MPhil, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Alentis Therapeutics AG; Basilea Pharmaceutica; Black Diamond Therapeutics, Inc.; Blueprint Medicines Corporation; Eisai Inc./H3Biomedicine; Exelixis, Inc.; Genentech, Inc.; Incyte Corporation; Kinnate Biopharma Inc.; Merck & Co., Inc.; QED Therapeutics; Relay Therapeutics; Servier Pharmaceuticals; Sirtex Medical Ltd; Surface Oncology; Taiho Oncology, Inc.; and TransThera Biosciences.

    Data Safety Monitoring Board for AstraZeneca.

 


 

Co-Chair/Planner

    Riad Salem, MD, MBA

    Professor of Radiology, Medicine, and Surgery

    Chief, Section of Vascular and Interventional Radiology

    Vice-Chairman, Image-Guided Therapy

    Department of Radiology

    Northwestern University Feinberg School of Medicine

    Chicago, Illinois


 

Riad Salem, MD, MBA, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AstraZeneca; Bard Pharmaceuticals; Boston Scientific Corporation; Cook Medical; Eisai Inc./Merck & Co., Inc.; and Genentech, Inc.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by an independent educational grant from AstraZeneca.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 2/26/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView


January 27, 2024
Matthew D. Galsky, MD
Credits: 1.50 CME / MOC / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum

Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum

Start

       
       

Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum


       

Media: Enduring Material
Activity Release Date: January 27, 2024
Activity Expiration Date: February 26, 2025
Time to Complete Activity: 90 minutes

Activity Description

Which treatment advances are making an impact for patients with bladder cancer? Approved and emerging therapeutic strategies that include immune checkpoint inhibitors, antibody–drug conjugates (ADCs) and other classes of agents are changing outcomes for patients with locally advanced or metastatic disease, while those with earlier-stage disease, including non-muscle invasive bladder cancer (NMIBC) or high-risk muscle-invasive bladder cancer (MIBC), are benefiting from bladder-sparing and perioperative approaches. Join PeerView and the Bladder Cancer Advocacy Network (BCAN) to learn how these treatment advances translate into practice, as clinical decision points are brought to life through discussion of real-world patient cases. Featuring a panel of experts, as well as resources and tools from BCAN, this activity offers learners practical guidance on incorporating the latest data on a variety of therapeutic strategies into the development of personalized treatment plans for patients throughout the disease continuum, creating team-based protocols for managing adverse events, and addressing inequities in diagnosis and treatment to increase access to state-of-the-art care for all patients.

Target Audience

This activity has been designed to meet the educational needs of oncologists, urologists, advanced practice clinicians, and other healthcare professionals involved in the management of bladder cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize current data on therapeutic strategies based on innovative drug delivery techniques, targeted agents, and modern immunotherapy regimens for the treatment of bladder cancer
  • Integrate approved and emerging therapeutic approaches into personalized treatment plans for patients with various stages of bladder cancer, considering evidence, guidelines, and principles of team-based and patient-centered care
  • Implement evidence- and team-based management protocols to address the suite of adverse events associated with bladder cancer therapies

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Matthew D. Galsky, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director of Genitourinary Medical Oncology
Co-Leader, Cancer Clinical Investigation Program
Associate Director for Translational Research
Tisch Cancer Institute
New York, New York

Matthew D. Galsky, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; Curis, Inc.; Daiichi Sankyo, Inc.; EMD Serono Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer and Seagen Inc.
Grant/Research Support from Bristol Myers Squibb and Merck & Co., Inc.

Faculty/Planner
Shilpa Gupta, MD
Clinical Professor of Medicine
Cleveland Clinic Lerner College of Medicine of CWRU
Director, Genitourinary Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Shilpa Gupta, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Pfizer; and Seattle Genetics (Seagen Inc.).
Grant/Research Support from Bristol Myers Squibb; EMD Serono Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; QED Therapeutics, Inc.; and Seattle Genetics (Seagen Inc.).
Speaker for Bristol Myers Squibb; Gilead Sciences, Inc.; and Seattle Genetics (Seagen Inc.).

Faculty/Planner
Andrea Necchi, MD
Associate Professor, Vita-Salute San Raffaele University
Director of Genitourinary Medical Oncology, IRCCS San Raffaele Hospital
Milan, Italy

Andrea Necchi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; AstraZeneca; Bristol Myers Squibb; CatalYm; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; and Seagen Inc.
Grant/Research Support from  Bristol Myers Squibb; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; and Merck & Co., Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


                   
                       
                       
                   
               
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through independent educational grants from AstraZeneca; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck & Co., Inc.; and Seagen and Astellas.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement


                   
                       
                       
                   
               
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points  in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants


                   
                       
                       
                   
               
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/26/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement


                   
                       
                       
                   
               
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


       

Copyright © 2000-2024, PeerView


   

       
       

Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum


       

Media: Enduring Material
Activity Release Date: January 27, 2024
Activity Expiration Date: February 26, 2025
Time to Complete Activity: 90 minutes

Activity Description

Which treatment advances are making an impact for patients with bladder cancer? Approved and emerging therapeutic strategies that include immune checkpoint inhibitors, antibody–drug conjugates (ADCs) and other classes of agents are changing outcomes for patients with locally advanced or metastatic disease, while those with earlier-stage disease, including non-muscle invasive bladder cancer (NMIBC) or high-risk muscle-invasive bladder cancer (MIBC), are benefiting from bladder-sparing and perioperative approaches. Join PeerView and the Bladder Cancer Advocacy Network (BCAN) to learn how these treatment advances translate into practice, as clinical decision points are brought to life through discussion of real-world patient cases. Featuring a panel of experts, as well as resources and tools from BCAN, this activity offers learners practical guidance on incorporating the latest data on a variety of therapeutic strategies into the development of personalized treatment plans for patients throughout the disease continuum, creating team-based protocols for managing adverse events, and addressing inequities in diagnosis and treatment to increase access to state-of-the-art care for all patients.

Target Audience

This activity has been designed to meet the educational needs of oncologists, urologists, advanced practice clinicians, and other healthcare professionals involved in the management of bladder cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize current data on therapeutic strategies based on innovative drug delivery techniques, targeted agents, and modern immunotherapy regimens for the treatment of bladder cancer
  • Integrate approved and emerging therapeutic approaches into personalized treatment plans for patients with various stages of bladder cancer, considering evidence, guidelines, and principles of team-based and patient-centered care
  • Implement evidence- and team-based management protocols to address the suite of adverse events associated with bladder cancer therapies

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Matthew D. Galsky, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director of Genitourinary Medical Oncology
Co-Leader, Cancer Clinical Investigation Program
Associate Director for Translational Research
Tisch Cancer Institute
New York, New York

Matthew D. Galsky, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; Curis, Inc.; Daiichi Sankyo, Inc.; EMD Serono Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer and Seagen Inc.
Grant/Research Support from Bristol Myers Squibb and Merck & Co., Inc.

Faculty/Planner
Shilpa Gupta, MD
Clinical Professor of Medicine
Cleveland Clinic Lerner College of Medicine of CWRU
Director, Genitourinary Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Shilpa Gupta, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Pfizer; and Seattle Genetics (Seagen Inc.).
Grant/Research Support from Bristol Myers Squibb; EMD Serono Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; QED Therapeutics, Inc.; and Seattle Genetics (Seagen Inc.).
Speaker for Bristol Myers Squibb; Gilead Sciences, Inc.; and Seattle Genetics (Seagen Inc.).

Faculty/Planner
Andrea Necchi, MD
Associate Professor, Vita-Salute San Raffaele University
Director of Genitourinary Medical Oncology, IRCCS San Raffaele Hospital
Milan, Italy

Andrea Necchi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; AstraZeneca; Bristol Myers Squibb; CatalYm; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; and Seagen Inc.
Grant/Research Support from  Bristol Myers Squibb; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; and Merck & Co., Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


                   
                       
                       
                   
               
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through independent educational grants from AstraZeneca; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck & Co., Inc.; and Seagen and Astellas.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement


                   
                       
                       
                   
               
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points  in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants


                   
                       
                       
                   
               
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/26/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement


                   
                       
                       
                   
               
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


       

Copyright © 2000-2024, PeerView


   
January 27, 2024
Robert Dreicer, MD, MS, MACP, FASCO
Credits: 1.5 CME / MOC / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies

Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies

Start

       
       

Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies


       

Media: Enduring Material
Activity Release Date: January 26, 2024
Activity Expiration Date: February 25, 2025
Time to Complete Activity: 90 minutes

Activity Description

Are you up for the challenge of modern treatment of prostate cancer? As the therapeutic landscape for localized and advanced prostate cancer has expanded greatly within the past few years, care team clinicians have a variety of options available or on the horizon for use in personalized care across the disease continuum. Approvals and positive results for high-risk biochemically recurrent localized disease and treatment intensification strategies for advanced disease with various regimens that include AR-targeting agents, PARP inhibitors, modern radioligands, CDK4/6 inhibitors, and IO + TKI combinations are set to further improve patient care.

Join PeerView and ZERO Prostate Cancer for a lively activity that includes friendly competition among a panel of experts that competes to answer questions on prostate cancer treatment while providing insight on evidence supporting the use of a variety of prostate cancer therapeutics and strategies for personalized treatment selection, including genetic and molecular testing, and increasing access to optimal care.

Target Audience

This activity has been designed to meet the educational needs of urologic and medical oncologists, urologists, advanced practice clinicians, and other healthcare professionals involved in the management of prostate cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the rationale and clinical data supporting contemporary treatment options, including the need for germline and somatic testing, that can inform personalized treatment selection for patients with prostate cancer
  • Design personalized team-based treatment protocols that incorporate key evidence-based strategies pertaining to approved and emerging therapeutics for patients with prostate cancer, including in the context of a clinical trial
  • Manage treatment-related adverse events from personalized treatment plans for patients with prostate cancer to promote optimal adherence, outcomes, and quality of life

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Robert Dreicer, MD, MS, MACP, FASCO
Section Head Medical Oncology
Deputy Director, University of Virginia Comprehensive Cancer Center
Associate Director for Clinical Research
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Robert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.

Faculty/Planner
Alicia K. Morgans, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Director, Survivorship Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Alicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.
Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.

Faculty/Planner
Neal D. Shore, MD, FACS
Medical Director, Carolina Urologic Research Center
Myrtle Beach, South Carolina

Neal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.

Faculty/Planner
Matthew R. Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine, Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Matthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


                   
                       
                       
                   
               
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement


                   
                       
                       
                   
               
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points  in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants


                   
                       
                       
                   
               
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/25/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement


                   
                       
                       
                   
               
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


       

Copyright © 2000-2024, PeerView


   

       
       

Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies


       

Media: Enduring Material
Activity Release Date: January 26, 2024
Activity Expiration Date: February 25, 2025
Time to Complete Activity: 90 minutes

Activity Description

Are you up for the challenge of modern treatment of prostate cancer? As the therapeutic landscape for localized and advanced prostate cancer has expanded greatly within the past few years, care team clinicians have a variety of options available or on the horizon for use in personalized care across the disease continuum. Approvals and positive results for high-risk biochemically recurrent localized disease and treatment intensification strategies for advanced disease with various regimens that include AR-targeting agents, PARP inhibitors, modern radioligands, CDK4/6 inhibitors, and IO + TKI combinations are set to further improve patient care.

Join PeerView and ZERO Prostate Cancer for a lively activity that includes friendly competition among a panel of experts that competes to answer questions on prostate cancer treatment while providing insight on evidence supporting the use of a variety of prostate cancer therapeutics and strategies for personalized treatment selection, including genetic and molecular testing, and increasing access to optimal care.

Target Audience

This activity has been designed to meet the educational needs of urologic and medical oncologists, urologists, advanced practice clinicians, and other healthcare professionals involved in the management of prostate cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the rationale and clinical data supporting contemporary treatment options, including the need for germline and somatic testing, that can inform personalized treatment selection for patients with prostate cancer
  • Design personalized team-based treatment protocols that incorporate key evidence-based strategies pertaining to approved and emerging therapeutics for patients with prostate cancer, including in the context of a clinical trial
  • Manage treatment-related adverse events from personalized treatment plans for patients with prostate cancer to promote optimal adherence, outcomes, and quality of life

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Robert Dreicer, MD, MS, MACP, FASCO
Section Head Medical Oncology
Deputy Director, University of Virginia Comprehensive Cancer Center
Associate Director for Clinical Research
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Robert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.

Faculty/Planner
Alicia K. Morgans, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Director, Survivorship Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Alicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.
Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.

Faculty/Planner
Neal D. Shore, MD, FACS
Medical Director, Carolina Urologic Research Center
Myrtle Beach, South Carolina

Neal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.

Faculty/Planner
Matthew R. Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine, Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Matthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


                   
                       
                       
                   
               
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement


                   
                       
                       
                   
               
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points  in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants


                   
                       
                       
                   
               
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/25/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement


                   
                       
                       
                   
               
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


       

Copyright © 2000-2024, PeerView


   
January 26, 2024
Sumanta Kumar Pal, MD, FASCO
Credits: 1.5 CME / MOC / NCPD / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies

Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies

Start

 
 

Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies


 

Media: Enduring Material

    Activity Release Date: January 26, 2024

    Activity Expiration Date: February 25, 2025

    Time to Complete Activity: 90 minutes


 

Activity Description


 

The rapid expansion in the renal cell carcinoma (RCC) therapeutic landscape has brought new hope for patients with kidney cancer along with increasing opportunities for healthcare professionals to provide personalized care across the disease spectrum. With FDA approvals of TKIs and immune checkpoint inhibitors in various disease settings, frontline treatment options include dual immunotherapy and IO plus TKI regimens, with some of these combinations showing benefit in patients with non–clear cell RCC, a population with limited clinical data and poor treatment outcomes. Critical therapeutic options are emerging in the perioperative setting, and further impact has been made in the refractory setting for patients who have been heavily pretreated.

   

    Join PeerView and the Kidney Cancer Research Alliance (KCCure) for an activity that features expert insights on the latest clinical trial and real-world evidence along with guidance on how to integrate scientific advances into modern RCC practice. Learn strategies for selecting and sequencing treatments, mitigating and managing adverse events, and incorporating shared decision-making into comprehensive, team-based care.


 

Target Audience


 

This activity has been designed to meet the educational needs of oncologists, urologists, advanced practice clinicians, nurses, and other healthcare professionals involved in the management of RCC.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Review evidence on treatment efficacy and safety of approved and emerging therapeutic options for patients with RCC across different disease stages and histologic subtypes

  •    
  • Design individualized treatment plans based on current evidence, as well as patient-, disease-, and treatment-specific factors for patients with RCC

  •    
  • Develop team-based approaches to anticipate, mitigate, and manage adverse events associated with treatments for patients with RCC to promote optimal adherence, outcomes, and quality of life

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Chair/Planner

    Sumanta Kumar Pal, MD, FASCO

    Professor, Department of Medical Oncology & Therapeutics Research

    Co-Director, Kidney Cancer Program

    City of Hope Comprehensive Cancer Center

    Duarte, California


 

Sumanta Kumar Pal, MD, FASCO, has a financial interest/relationship or affiliation in the form of:

    Grant/Research Support from Allogene Therapeutics; CRISPR Therapeutics; Eisai Co., Ltd.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Pfizer all paid to institution.

 


 

Faculty/Planner

    Pedro C. Barata, MD, MSc, FACP

    Co-Leader Genitourinary (GU) Disease Team

    Director of GU Medical Oncology Research Program

    University Hospitals Seidman Cancer Center

    Associate Professor of Medicine

    Case Western Reserve University

    Case Comprehensive Cancer Center

    Cleveland, Ohio


 

Pedro C. Barata, MD, MSc, FACP, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Astellas Pharma Inc.; AVEO Pharmaceuticals, Inc; Bristol Myers Squibb; Clovis Oncology; EMD Serono; Eisai Co., Ltd.; Exelixis, Inc.; Ipsen Biopharmaceuticals, Inc.; Pfizer; and Sanofi.

    Grant/Research Support from EMD Serono and Exelixis, Inc.

    Speakers Bureau participant with Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; and Sanofi.

 


 

Faculty/Planner

    David F. McDermott, MD

    Chief, Medical Oncology

    Beth Israel Deaconess Medical Center

    Leader, Dana-Farber Harvard Cancer Center Kidney Cancer Program

    Professor of Medicine

    Harvard Medical School

    Boston, Massachusetts


 

David F. McDermott, MD, has no financial interests/relationships or affiliations in relation to this activity.


 

Faculty/Planner

    Tian Zhang, MD, MHS

    Associate Professor, Division of Hematology and Oncology

    Department of Internal Medicine

    UT Southwestern Medical Center

    Harold C. Simmons Comprehensive Cancer Center

    Dallas, Texas


 

Tian Zhang, MD, MHS, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Aravive; AstraZeneca; AVEO Pharmaceuticals, Inc.; Bayer Corporation; Bristol Myers Squibb; Caris Life Sciences; Eisai Co., Ltd.; EMD Serono; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seagen Inc.

    Grant/Research Support from ALX Oncology; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; and Tempus.

    Other Financial or Material Support for leadership or fiduciary role in Kidney Cancer Association (KCA) Medical Steering Committee; Kidney Cancer Research Alliance (KCCure) Scientific Advisory Board; and National Cancer Institute (NCI) Steering Renal Task Force.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Kidney Cancer Research Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This educational activity is supported through medical education grants from AVEO Pharmaceuticals, Inc., Bristol Myers Squibb, Eisai Inc., Exelixis, Inc., and Merck & Co., Inc.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/25/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/NCPD/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView



 
 

Advancing Personalized Care in RCC: Navigating Rapid Therapeutic Expansion and Sequencing Strategies


 

Media: Enduring Material

    Activity Release Date: January 26, 2024

    Activity Expiration Date: February 25, 2025

    Time to Complete Activity: 90 minutes


 

Activity Description


 

The rapid expansion in the renal cell carcinoma (RCC) therapeutic landscape has brought new hope for patients with kidney cancer along with increasing opportunities for healthcare professionals to provide personalized care across the disease spectrum. With FDA approvals of TKIs and immune checkpoint inhibitors in various disease settings, frontline treatment options include dual immunotherapy and IO plus TKI regimens, with some of these combinations showing benefit in patients with non–clear cell RCC, a population with limited clinical data and poor treatment outcomes. Critical therapeutic options are emerging in the perioperative setting, and further impact has been made in the refractory setting for patients who have been heavily pretreated.

   

    Join PeerView and the Kidney Cancer Research Alliance (KCCure) for an activity that features expert insights on the latest clinical trial and real-world evidence along with guidance on how to integrate scientific advances into modern RCC practice. Learn strategies for selecting and sequencing treatments, mitigating and managing adverse events, and incorporating shared decision-making into comprehensive, team-based care.


 

Target Audience


 

This activity has been designed to meet the educational needs of oncologists, urologists, advanced practice clinicians, nurses, and other healthcare professionals involved in the management of RCC.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Review evidence on treatment efficacy and safety of approved and emerging therapeutic options for patients with RCC across different disease stages and histologic subtypes

  •    
  • Design individualized treatment plans based on current evidence, as well as patient-, disease-, and treatment-specific factors for patients with RCC

  •    
  • Develop team-based approaches to anticipate, mitigate, and manage adverse events associated with treatments for patients with RCC to promote optimal adherence, outcomes, and quality of life

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Chair/Planner

    Sumanta Kumar Pal, MD, FASCO

    Professor, Department of Medical Oncology & Therapeutics Research

    Co-Director, Kidney Cancer Program

    City of Hope Comprehensive Cancer Center

    Duarte, California


 

Sumanta Kumar Pal, MD, FASCO, has a financial interest/relationship or affiliation in the form of:

    Grant/Research Support from Allogene Therapeutics; CRISPR Therapeutics; Eisai Co., Ltd.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Pfizer all paid to institution.

 


 

Faculty/Planner

    Pedro C. Barata, MD, MSc, FACP

    Co-Leader Genitourinary (GU) Disease Team

    Director of GU Medical Oncology Research Program

    University Hospitals Seidman Cancer Center

    Associate Professor of Medicine

    Case Western Reserve University

    Case Comprehensive Cancer Center

    Cleveland, Ohio


 

Pedro C. Barata, MD, MSc, FACP, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Astellas Pharma Inc.; AVEO Pharmaceuticals, Inc; Bristol Myers Squibb; Clovis Oncology; EMD Serono; Eisai Co., Ltd.; Exelixis, Inc.; Ipsen Biopharmaceuticals, Inc.; Pfizer; and Sanofi.

    Grant/Research Support from EMD Serono and Exelixis, Inc.

    Speakers Bureau participant with Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; and Sanofi.

 


 

Faculty/Planner

    David F. McDermott, MD

    Chief, Medical Oncology

    Beth Israel Deaconess Medical Center

    Leader, Dana-Farber Harvard Cancer Center Kidney Cancer Program

    Professor of Medicine

    Harvard Medical School

    Boston, Massachusetts


 

David F. McDermott, MD, has no financial interests/relationships or affiliations in relation to this activity.


 

Faculty/Planner

    Tian Zhang, MD, MHS

    Associate Professor, Division of Hematology and Oncology

    Department of Internal Medicine

    UT Southwestern Medical Center

    Harold C. Simmons Comprehensive Cancer Center

    Dallas, Texas


 

Tian Zhang, MD, MHS, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Aravive; AstraZeneca; AVEO Pharmaceuticals, Inc.; Bayer Corporation; Bristol Myers Squibb; Caris Life Sciences; Eisai Co., Ltd.; EMD Serono; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seagen Inc.

    Grant/Research Support from ALX Oncology; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; and Tempus.

    Other Financial or Material Support for leadership or fiduciary role in Kidney Cancer Association (KCA) Medical Steering Committee; Kidney Cancer Research Alliance (KCCure) Scientific Advisory Board; and National Cancer Institute (NCI) Steering Renal Task Force.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Kidney Cancer Research Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This educational activity is supported through medical education grants from AVEO Pharmaceuticals, Inc., Bristol Myers Squibb, Eisai Inc., Exelixis, Inc., and Merck & Co., Inc.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/25/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/NCPD/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView


January 26, 2024
Aditya Bardia, MD, MPH, FASCO
Credits: 1.0 CME / MOC / CC / NCPD / AAPA / IPCE
PeerView Institute
Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer: Unlocking the Potential of Adjuvant CDK4/6 Inhibitors to Reduce the Risk of Recurrence and Improve Outcomes for Diverse Patient Populations With HR+/HER2- Early Breast Cancer

Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer: Unlocking the Potential of Adjuvant CDK4/6 Inhibitors to Reduce the Risk of Recurrence and Improve Outcomes for Diverse Patient Populations With HR+/HER2- Early Breast Cancer

Start

 
 

Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer: Unlocking the Potential of Adjuvant CDK4/6 Inhibitors to Reduce the Risk of Recurrence and Improve Outcomes for Diverse Patient Populations With HR+/HER2- Early Breast Cancer


 

Media: Enduring Material

    Activity Release Date: January 26, 2024

    Activity Expiration Date: January 25, 2025

    Time to Complete Activity: 60 minutes


 

Activity Description


 

In this activity, Dr. Aditya Bardia reviews the latest evidence for adjuvant CDK4/6 inhibitors in HR+/HER2- early breast cancer (EBC) and discusses how these agents can reduce the risk of recurrence and improve outcomes.


 

Target Audience


 

This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the care of patients with HR+/HER- EBC.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Formulate individualized treatment plans inclusive of adjuvant CDK4/6 inhibitors and ET for patients with HR+/HER2- EBC based on latest evidence and recommendations

  •    
  • Develop a team-based plan for patients with EBC undergoing adjuvant systemic therapy to closely monitor them, diagnose and manage AEs, and achieve optimal treatment adherence and persistence

  •    
  • Implement strategies to recognize and address disparities in breast cancer for diverse racial and ethnic groups, with a goal of eliminating barriers and ensuring optimal care for all patients, especially minority populations in community settings

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Chair/Planner

    Aditya Bardia, MD, MPH, FASCO

    Professor of Medicine

    Geffen School of Medicine at UCLA

    Director, Breast Oncology Program

    Assistant Chief (Translational Research)

    Medical Oncology Division

    Director of Translational Research Integration

    UCLA Health Jonsson Comprehensive Cancer Center

    Los Angeles, California


 

Aditya Bardia, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Daiichi Sankyo Inc./AstraZeneca; Foundation Medicine, Inc.; Genentech, Inc.; Immunomedics, Inc./Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Phillips Healthcare Corporation; Radius Health, Inc.; and Sanofi.

    Grant/Research Support from Daiichi Sankyo Inc./AstraZeneca; Genentech, Inc.; Immunomedics, Inc./Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Radius Health, Inc.; and Sanofi.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
    
    

 
   
     
       
       
     
   
 
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Continuing Certification Statement


 
   
     
       
       
     
   
 
ABPath The activity titled “Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer: Unlocking the Potential of Adjuvant CDK4/6 Inhibitors to Reduce the Risk of Recurrence and Improve Outcomes for Diverse Patient Populations With HR+/HER2- Early Breast Cancer” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 1/25/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/CC/NCPD/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView



 
 

Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer: Unlocking the Potential of Adjuvant CDK4/6 Inhibitors to Reduce the Risk of Recurrence and Improve Outcomes for Diverse Patient Populations With HR+/HER2- Early Breast Cancer


 

Media: Enduring Material

    Activity Release Date: January 26, 2024

    Activity Expiration Date: January 25, 2025

    Time to Complete Activity: 60 minutes


 

Activity Description


 

In this activity, Dr. Aditya Bardia reviews the latest evidence for adjuvant CDK4/6 inhibitors in HR+/HER2- early breast cancer (EBC) and discusses how these agents can reduce the risk of recurrence and improve outcomes.


 

Target Audience


 

This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the care of patients with HR+/HER- EBC.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Formulate individualized treatment plans inclusive of adjuvant CDK4/6 inhibitors and ET for patients with HR+/HER2- EBC based on latest evidence and recommendations

  •    
  • Develop a team-based plan for patients with EBC undergoing adjuvant systemic therapy to closely monitor them, diagnose and manage AEs, and achieve optimal treatment adherence and persistence

  •    
  • Implement strategies to recognize and address disparities in breast cancer for diverse racial and ethnic groups, with a goal of eliminating barriers and ensuring optimal care for all patients, especially minority populations in community settings

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Chair/Planner

    Aditya Bardia, MD, MPH, FASCO

    Professor of Medicine

    Geffen School of Medicine at UCLA

    Director, Breast Oncology Program

    Assistant Chief (Translational Research)

    Medical Oncology Division

    Director of Translational Research Integration

    UCLA Health Jonsson Comprehensive Cancer Center

    Los Angeles, California


 

Aditya Bardia, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Daiichi Sankyo Inc./AstraZeneca; Foundation Medicine, Inc.; Genentech, Inc.; Immunomedics, Inc./Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Phillips Healthcare Corporation; Radius Health, Inc.; and Sanofi.

    Grant/Research Support from Daiichi Sankyo Inc./AstraZeneca; Genentech, Inc.; Immunomedics, Inc./Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Radius Health, Inc.; and Sanofi.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
    
    

 
   
     
       
       
     
   
 
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Continuing Certification Statement


 
   
     
       
       
     
   
 
ABPath The activity titled “Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer: Unlocking the Potential of Adjuvant CDK4/6 Inhibitors to Reduce the Risk of Recurrence and Improve Outcomes for Diverse Patient Populations With HR+/HER2- Early Breast Cancer” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 1/25/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/CC/NCPD/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView


January 26, 2024
Anjali Tiku Owens, MD
Credits: 1.0 CME / MOC / NCPD / AAPA
PVI, PeerView Institute for Medical Education
Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes

Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes

Start

       
       

Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes


       

Media: Enduring Material
Activity Release Date: January 22, 2024
Activity Expiration Date: January 21, 2025
Time to Complete Activity: 60 minutes

Activity Description

Hypertrophic cardiomyopathy (HCM) occurs with an estimated prevalence of as many as 1 in 200 people, with a mortality rate about 3 times greater compared with individuals of a similar age without HCM. The clinical course of HCM can vary greatly depending upon the individual, with some patients being asymptomatic and others experiencing extreme fatigue, dyspnea, chest pain, arrhythmias, and stroke. Experiencing symptoms is the most common reason patients first seek care, but less than half of symptomatic HCM patients initially seek care from a cardiologist.

In this learning opportunity, a cardiology expert and a primary care expert sit down to discuss how primary care professionals can participate in the diagnosis and management of HCM. By the end, learners will have increased their ability to recognize symptoms of and risk factors for HCM and their knowledge of screening tools for patients suspected of having HCM. Learners will also better understand how to manage common comorbidities and how to participate in follow-up care and monitoring of patients diagnosed with HCM.

Target Audience

This activity has been designed to meet the educational needs of primary care clinicians including family medicine and internal medicine physicians, advanced practice clinicians, nurses, and other clinicians involved in the care of patients with or at risk for hypertrophic cardiomyopathy (HCM).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Recognize symptoms and aspects of family history that may indicate risk for HCM or require differential diagnosis through further evaluation or screening
  • Evaluate patients suspected of having HCM using tools such as ECG and echocardiography, including referral to specialty care, as appropriate
  • Manage the comorbidities commonly associated with HCM (eg, atrial fibrillation, obesity, sleep apnea, and hypertension) in a shared-care model with specialty care providers
  • Participate in follow-up care and monitoring of patients diagnosed with HCM, including checking for drug–drug interactions to ensure timely and safe treatment

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Anjali Tiku Owens, MD
Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure
Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

Anjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.
Grant/Research Support from Bristol Myers Squibb.

Faculty/Planner
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Associate Director
Family Medicine Residency Program
Jefferson Health - Abington
Abington, Pennsylvania

Neil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.
Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.
Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


                   
                       
                       
                   
               
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement


                   
                       
                       
                   
               
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Physician Assistants


                   
                       
                       
                   
               
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 1/21/2025. PAs should only claim credit commensurate with the extent of their participation.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


       

Copyright © 2000-2024, PeerView


   

       
       

Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes


       

Media: Enduring Material
Activity Release Date: January 22, 2024
Activity Expiration Date: January 21, 2025
Time to Complete Activity: 60 minutes

Activity Description

Hypertrophic cardiomyopathy (HCM) occurs with an estimated prevalence of as many as 1 in 200 people, with a mortality rate about 3 times greater compared with individuals of a similar age without HCM. The clinical course of HCM can vary greatly depending upon the individual, with some patients being asymptomatic and others experiencing extreme fatigue, dyspnea, chest pain, arrhythmias, and stroke. Experiencing symptoms is the most common reason patients first seek care, but less than half of symptomatic HCM patients initially seek care from a cardiologist.

In this learning opportunity, a cardiology expert and a primary care expert sit down to discuss how primary care professionals can participate in the diagnosis and management of HCM. By the end, learners will have increased their ability to recognize symptoms of and risk factors for HCM and their knowledge of screening tools for patients suspected of having HCM. Learners will also better understand how to manage common comorbidities and how to participate in follow-up care and monitoring of patients diagnosed with HCM.

Target Audience

This activity has been designed to meet the educational needs of primary care clinicians including family medicine and internal medicine physicians, advanced practice clinicians, nurses, and other clinicians involved in the care of patients with or at risk for hypertrophic cardiomyopathy (HCM).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Recognize symptoms and aspects of family history that may indicate risk for HCM or require differential diagnosis through further evaluation or screening
  • Evaluate patients suspected of having HCM using tools such as ECG and echocardiography, including referral to specialty care, as appropriate
  • Manage the comorbidities commonly associated with HCM (eg, atrial fibrillation, obesity, sleep apnea, and hypertension) in a shared-care model with specialty care providers
  • Participate in follow-up care and monitoring of patients diagnosed with HCM, including checking for drug–drug interactions to ensure timely and safe treatment

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Anjali Tiku Owens, MD
Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure
Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

Anjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.
Grant/Research Support from Bristol Myers Squibb.

Faculty/Planner
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Associate Director
Family Medicine Residency Program
Jefferson Health - Abington
Abington, Pennsylvania

Neil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.
Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.
Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


                   
                       
                       
                   
               
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement


                   
                       
                       
                   
               
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Physician Assistants


                   
                       
                       
                   
               
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 1/21/2025. PAs should only claim credit commensurate with the extent of their participation.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


       

Copyright © 2000-2024, PeerView


   
January 22, 2024
Ghassan Abou-Alfa, MD, MBA
Credits: 1.5 CME / MOC / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches

Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches

Start

 
 

Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches


 

Media: Enduring Material

    Activity Release Date: January 19, 2024

    Activity Expiration Date: February 18, 2025

    Time to Complete Activity: 90 minutes


 

Activity Description


 

As immunotherapy and targeted platforms transform hepatocellular carcinoma (HCC) management, it is becoming increasingly important for oncologists to “calibrate care” across all stages of disease. A recent wave of approved therapeutic regimens, including immunotherapy/anti-VEGF combinations (eg, atezolizumab and bevacizumab), dual immunotherapy combinations (ie, durvalumab-tremelimumab), and next-generation TKIs (ie, lenvatinib) has been introduced in the upfront setting. Recent additions to the second-line setting have delivered improved options for patients with HCC including multikinase inhibitors (ie, cabozantinib and regorafenib) and immune checkpoint inhibitors (eg, pembrolizumab and nivolumab). Furthermore, emerging data on other up-and-coming targeted platforms have shown the benefit of combining immunotherapy with LRT for BCLC B disease and the utility of adjuvant immunotherapy in resectable disease.

   

    In collaboration with Blue Faery: The Adrienne Wilson Liver Cancer Association, this MasterClass & Case Forum event will consist of a series of concise, foundational lectures that support the utilization of modern targeted and immunotherapy regimens across all stages of HCC. Each MasterClass lecture segment will lead into a Case Forum discussion anchored by real-world cases informed by the evidence. Learn the latest data on important topics such as multimodal approaches in intermediate-stage HCC, emerging adjuvant strategies in early-stage HCC, and adverse event management.


 

Target Audience


 

This activity has been designed to meet the educational needs of gastrointestinal oncologists, medical oncologists, and advanced practice clinicians involved in the management of HCC.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Cite current and emerging clinical evidence supporting the integration of immunotherapy and targeted platforms for the management of HCC

  •    
  • Apply the latest safety/efficacy evidence supporting immunotherapy and targeted agents when developing personalized treatment plans for patients with HCC across all stages of disease

  •    
  • Leverage the wider GI-oncology care team to address practical aspects of care when integrating modern therapeutic approaches, including patient consultation and treatment-related adverse event management

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Chair/Planner

    Ghassan Abou-Alfa, MD, MBA

    New York, New York

    Professor

    Memorial Sloan Kettering Cancer Center

    Weill Cornell College at Cornell University

    Trinity College Dublin


 

Ghassan Abou-Alfa, MD, MBA, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AstraZeneca; Autem Therapeutics; Berry Genomics; BioNTech; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Incyte; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Neogene Therapeutics; NewBridge Pharmaceuticals; Novartis Pharmaceuticals Corporation; Servier Laboratories; Tempus; Vector; and Yiviva.

    Grant/Research Support from Agenus Inc.; Arcus Biosciences, Inc.; AstraZeneca; BioNTech; Bristol Myers Squibb; Elicio Therapeutics Inc; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Helsinn Healthcare SA; Parker Institute for Cancer Immunotherapy; Pertzye; Puma Biotechnology, Inc.; QED Therapeutics; and Yiviva.

 


 

Faculty/Planner

    Anthony El-Khoueiry, MD

    Associate Professor of Medicine

    Associate Director for Clinical Research

    Phase I Program Director

    USC Norris Comprehensive Cancer Center

    Los Angeles, California


 

Anthony El-Khoueiry, MD, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AstraZeneca; Exelixis, Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Merck & Co., Inc.; Qurient; and Senti Biosciences.

    Grant/Research Support from Astex Pharmaceuticals; AstraZeneca; Auransa Inc.; and Fulgent Pharma.

 


 

Faculty/Planner

    Ahmed Omar Kaseb, MD, CMQ

    John E. and Dorothy J. Harris Professorship in Gastrointestinal Cancer Research

    Member, National Hepatobiliary Task Force, NCI, USA

    Tenured Professor and Director, Hepatocellular Carcinoma Program

    Director, MD Anderson HCC SPORE

    Department of Gastrointestinal Medical Oncology

    The University of Texas MD Anderson Cancer Center

    Houston, Texas


 

Ahmed Omar Kaseb, MD, CMQ, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; Genentech, Inc.; Merck & Co., Inc.; and Pfizer.

    Grant/Research Support from Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; Genentech, Inc.; Merck & Co., Inc.; Pfizer; and Tvardi Therapeutics.

 


 

Faculty/Planner

    Stacey M. Stein, MD

    Associate Professor of Medicine

    Assistant Medical Director of the Clinical Trials Office

    Leader, Hepatobiliary Program

    Yale School of Medicine

    New Haven, Connecticut


 

Stacey M. Stein, MD, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AstraZeneca; Eisai Inc.; Exelixis, Inc.; and Genentech, Inc.

    Data Safety Monitoring Board for Aethlon Medical, Inc.and Genentech, Inc.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Planner

    Andrea Wilson Woods

    President & Founder, Blue Faery


 

Andrea Wilson Woods has a financial interest/relationship or affiliation in the form of:

    Consultant for AstraZeneca and Humanise Health.


 

Accreditation, Support, and Credit


    
    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Blue Faery: The Adrienne Wilson Liver Cancer Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This educational activity is supported through independent educational grants from AstraZeneca, Eisai Inc., Exelixis, Inc., Merck & Co., Inc., and Novocure, Inc.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points  in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/18/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView



 
 

Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches


 

Media: Enduring Material

    Activity Release Date: January 19, 2024

    Activity Expiration Date: February 18, 2025

    Time to Complete Activity: 90 minutes


 

Activity Description


 

As immunotherapy and targeted platforms transform hepatocellular carcinoma (HCC) management, it is becoming increasingly important for oncologists to “calibrate care” across all stages of disease. A recent wave of approved therapeutic regimens, including immunotherapy/anti-VEGF combinations (eg, atezolizumab and bevacizumab), dual immunotherapy combinations (ie, durvalumab-tremelimumab), and next-generation TKIs (ie, lenvatinib) has been introduced in the upfront setting. Recent additions to the second-line setting have delivered improved options for patients with HCC including multikinase inhibitors (ie, cabozantinib and regorafenib) and immune checkpoint inhibitors (eg, pembrolizumab and nivolumab). Furthermore, emerging data on other up-and-coming targeted platforms have shown the benefit of combining immunotherapy with LRT for BCLC B disease and the utility of adjuvant immunotherapy in resectable disease.

   

    In collaboration with Blue Faery: The Adrienne Wilson Liver Cancer Association, this MasterClass & Case Forum event will consist of a series of concise, foundational lectures that support the utilization of modern targeted and immunotherapy regimens across all stages of HCC. Each MasterClass lecture segment will lead into a Case Forum discussion anchored by real-world cases informed by the evidence. Learn the latest data on important topics such as multimodal approaches in intermediate-stage HCC, emerging adjuvant strategies in early-stage HCC, and adverse event management.


 

Target Audience


 

This activity has been designed to meet the educational needs of gastrointestinal oncologists, medical oncologists, and advanced practice clinicians involved in the management of HCC.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Cite current and emerging clinical evidence supporting the integration of immunotherapy and targeted platforms for the management of HCC

  •    
  • Apply the latest safety/efficacy evidence supporting immunotherapy and targeted agents when developing personalized treatment plans for patients with HCC across all stages of disease

  •    
  • Leverage the wider GI-oncology care team to address practical aspects of care when integrating modern therapeutic approaches, including patient consultation and treatment-related adverse event management

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Chair/Planner

    Ghassan Abou-Alfa, MD, MBA

    New York, New York

    Professor

    Memorial Sloan Kettering Cancer Center

    Weill Cornell College at Cornell University

    Trinity College Dublin


 

Ghassan Abou-Alfa, MD, MBA, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AstraZeneca; Autem Therapeutics; Berry Genomics; BioNTech; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Incyte; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Neogene Therapeutics; NewBridge Pharmaceuticals; Novartis Pharmaceuticals Corporation; Servier Laboratories; Tempus; Vector; and Yiviva.

    Grant/Research Support from Agenus Inc.; Arcus Biosciences, Inc.; AstraZeneca; BioNTech; Bristol Myers Squibb; Elicio Therapeutics Inc; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Helsinn Healthcare SA; Parker Institute for Cancer Immunotherapy; Pertzye; Puma Biotechnology, Inc.; QED Therapeutics; and Yiviva.

 


 

Faculty/Planner

    Anthony El-Khoueiry, MD

    Associate Professor of Medicine

    Associate Director for Clinical Research

    Phase I Program Director

    USC Norris Comprehensive Cancer Center

    Los Angeles, California


 

Anthony El-Khoueiry, MD, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AstraZeneca; Exelixis, Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Merck & Co., Inc.; Qurient; and Senti Biosciences.

    Grant/Research Support from Astex Pharmaceuticals; AstraZeneca; Auransa Inc.; and Fulgent Pharma.

 


 

Faculty/Planner

    Ahmed Omar Kaseb, MD, CMQ

    John E. and Dorothy J. Harris Professorship in Gastrointestinal Cancer Research

    Member, National Hepatobiliary Task Force, NCI, USA

    Tenured Professor and Director, Hepatocellular Carcinoma Program

    Director, MD Anderson HCC SPORE

    Department of Gastrointestinal Medical Oncology

    The University of Texas MD Anderson Cancer Center

    Houston, Texas


 

Ahmed Omar Kaseb, MD, CMQ, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; Genentech, Inc.; Merck & Co., Inc.; and Pfizer.

    Grant/Research Support from Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; Genentech, Inc.; Merck & Co., Inc.; Pfizer; and Tvardi Therapeutics.

 


 

Faculty/Planner

    Stacey M. Stein, MD

    Associate Professor of Medicine

    Assistant Medical Director of the Clinical Trials Office

    Leader, Hepatobiliary Program

    Yale School of Medicine

    New Haven, Connecticut


 

Stacey M. Stein, MD, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AstraZeneca; Eisai Inc.; Exelixis, Inc.; and Genentech, Inc.

    Data Safety Monitoring Board for Aethlon Medical, Inc.and Genentech, Inc.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Planner

    Andrea Wilson Woods

    President & Founder, Blue Faery


 

Andrea Wilson Woods has a financial interest/relationship or affiliation in the form of:

    Consultant for AstraZeneca and Humanise Health.


 

Accreditation, Support, and Credit


    
    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Blue Faery: The Adrienne Wilson Liver Cancer Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This educational activity is supported through independent educational grants from AstraZeneca, Eisai Inc., Exelixis, Inc., Merck & Co., Inc., and Novocure, Inc.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points  in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/18/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView


January 19, 2024
Milind Javle, MD
Credits: 1.5 CME / MOC / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice

Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice

Start

       
       

Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice


       

Media: Enduring Material
Activity Release Date: January 19, 2024
Activity Expiration Date: February 18, 2025
Time to Complete Activity: 90 minutes

Activity Description

Groundbreaking science in personalized therapeutic approaches for advanced biliary tract cancers (BTCs) has resulted in the expansion of a diverse management model, empowering oncologists to battle the disease, as emerging evidence continues to reshape treatment planning based on patient-specific findings. These developments have led to the approval of several immune-based and molecularly targeted therapies for the clinical management of advanced BTCs. Through a case-based discussion, experts will provide valuable insight on the practical aspects of integrating these new and emerging therapeutic platforms into your clinical practice.

This Seminars and Tumor Board activity, based on a recent live symposium and produced in collaboration with the Cholangiocarcinoma Foundation (CCF), pairs real-world case scenarios with the practice-changing evidence that guides treatment selection for the management of advanced BTCs. PeerView’s collaboration with the CCF includes their educational resources and patient stories to improve patient education, engagement in care, and shared decision-making.

Target Audience

This activity has been designed to meet the educational needs of oncologists, gastroenterologists, advanced practice clinicians (NPs/PAs), and other relevant healthcare professionals involved in the management of biliary cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the latest clinical evidence supporting the use of modern and emerging therapeutic approaches, including immunotherapy and targeted platforms, for the management of BTC
  • Utilize biomarker findings, current evidence, and guideline recommendations to build individualized treatment regimens for patients with advanced BTC
  • Develop team-based strategies to address practical considerations of care, including patient education and AE management

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Milind Javle, MD
Professor, Department of Gastrointestinal (GI) Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Milind Javle, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.

Faculty/Planner
Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center (All Regions)
Consortium Chair, Academic and Community Cancer Research United (ACCRU)
Phoenix, Arizona

Tanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.
Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.
Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.
Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.

Faculty/Planner
Rachna Shroff, MD, MS, FASCO
Chief, Division of Hematology/Oncology, UA COM-T
Associate Director of Clinical Investigations, UACC
Associate Dean, Clinical and Translational Research, UA COM-T
Professor of Medicine
University of Arizona Cancer Center (UACC)
University of Arizona College of Medicine – Tucson (UA COM-T)
Tucson, Arizona

Rachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.
Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


                   
                       
                       
                   
               
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement


                   
                       
                       
                   
               
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points  in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants


                   
                       
                       
                   
               
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/18/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement


                   
                       
                       
                   
               
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


       

Copyright © 2000-2024, PeerView


   

       
       

Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice


       

Media: Enduring Material
Activity Release Date: January 19, 2024
Activity Expiration Date: February 18, 2025
Time to Complete Activity: 90 minutes

Activity Description

Groundbreaking science in personalized therapeutic approaches for advanced biliary tract cancers (BTCs) has resulted in the expansion of a diverse management model, empowering oncologists to battle the disease, as emerging evidence continues to reshape treatment planning based on patient-specific findings. These developments have led to the approval of several immune-based and molecularly targeted therapies for the clinical management of advanced BTCs. Through a case-based discussion, experts will provide valuable insight on the practical aspects of integrating these new and emerging therapeutic platforms into your clinical practice.

This Seminars and Tumor Board activity, based on a recent live symposium and produced in collaboration with the Cholangiocarcinoma Foundation (CCF), pairs real-world case scenarios with the practice-changing evidence that guides treatment selection for the management of advanced BTCs. PeerView’s collaboration with the CCF includes their educational resources and patient stories to improve patient education, engagement in care, and shared decision-making.

Target Audience

This activity has been designed to meet the educational needs of oncologists, gastroenterologists, advanced practice clinicians (NPs/PAs), and other relevant healthcare professionals involved in the management of biliary cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the latest clinical evidence supporting the use of modern and emerging therapeutic approaches, including immunotherapy and targeted platforms, for the management of BTC
  • Utilize biomarker findings, current evidence, and guideline recommendations to build individualized treatment regimens for patients with advanced BTC
  • Develop team-based strategies to address practical considerations of care, including patient education and AE management

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Milind Javle, MD
Professor, Department of Gastrointestinal (GI) Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Milind Javle, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.

Faculty/Planner
Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center (All Regions)
Consortium Chair, Academic and Community Cancer Research United (ACCRU)
Phoenix, Arizona

Tanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.
Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.
Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.
Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.

Faculty/Planner
Rachna Shroff, MD, MS, FASCO
Chief, Division of Hematology/Oncology, UA COM-T
Associate Director of Clinical Investigations, UACC
Associate Dean, Clinical and Translational Research, UA COM-T
Professor of Medicine
University of Arizona Cancer Center (UACC)
University of Arizona College of Medicine – Tucson (UA COM-T)
Tucson, Arizona

Rachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.
Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


                   
                       
                       
                   
               
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement


                   
                       
                       
                   
               
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points  in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants


                   
                       
                       
                   
               
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/18/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement


                   
                       
                       
                   
               
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


       

Copyright © 2000-2024, PeerView


   
January 19, 2024
Erika Hamilton, MD
Credits: 1.0 CME / MOC / NCPD / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC

Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC

Start

Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC

Media: Enduring Material
Activity Release Date: January 18, 2024
Activity Expiration Date: February 17, 2025
Time to Complete Activity: 60 minutes

Activity Description

Despite their established role in the treatment of HR+, HER2- metastatic breast cancer (MBC) and accumulating evidence supporting their adjuvant use in HR+, HER2- early breast cancer (EBC), questions still surround CDK4/6 inhibitors and their use. While these agents were historically thought to be largely similar and interchangeable, evolving data from clinical and translational studies have shown that CDK4/6 inhibitors are not the same. They have key differences in their chemical, biologic, pharmacologic, and clinical features and different toxicity profiles, despite all being orally bioavailable. Therefore, we must re-evaluate how we approach CDK4/6 inhibitors and integrate them into individualized treatment plans for patients throughout the disease continuum, as well as consider what that looks like in the real-world setting and how to make the most of them and their distinct properties in the frontline setting and beyond?

In this activity, based on a recent live virtual workshop, learners receive an in-depth, expert assessment of CDK4/6 inhibitors in HR+, HER2- EBC and MBC, which provides the foundation for case-based discussions and tool-based demonstrations of algorithmic decision aids designed to guide risk assessment, candidate selection for therapy, and the optimal delivery of treatment to reduce the risk of recurrence in individuals with HR+, HER2- EBC before transitioning to HR+, HER2- MBC to demonstrate patient evaluation, identify factors for prognostication, and model treatment planning, selection, and sequencing throughout the advance disease continuum. Additionally, the panel shares strategies to mitigate and manage common adverse reactions associated with CDK4/6 inhibitors to improve treatment adherence and persistence.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with early and metastatic breast cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients with HR+, HER2- EBC and MBC via thorough assessment of clinical, pathologic, genomic, and other relevant factors
  • Design individualized treatment protocols integrating CDK4/6 inhibitor therapy for patients with HR+, HER2- EBC and MBC based on the latest evidence, guidelines, and tumor/disease characteristics
  • Develop team-based strategies to achieve optimal treatment adherence/persistence and prevention/mitigation of AEs associated with different CDK4/6 inhibitors in the treatment of HR+, HER2- EBC and MBC

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Erika Hamilton, MD
Chair, Breast Executive Committee
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Erika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).
Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.; Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics; Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks Inc. (all paid to institution).

Faculty/Planner
Komal Jhaveri, MD, FACP
Patricia and James Cayne Chair for Junior Faculty
Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center/Evelyn H. Lauder Breast and Imaging Center
New York, New York

Komal Jhaveri, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.
Grant/Research Support from ADC Therapeutics SA; AstraZeneca; Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion Therapeutics; and Zymeworks Inc.

Faculty/Planner
Professor Stephen Johnston, MA, PhD
Professor of Breast Cancer Medicine & Head of Medical Oncology
Consultant Medical Oncologist & Head of The Breast Unit
The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research
Chelsea, London, United Kingdom

Professor Stephen Johnston, MA, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and Sanofi.
Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and Puma Biotechnology, Inc.
Speakers Bureau participant with AstraZeneca; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; and Pfizer.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-015-H01-P
Type of Activity: Application

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/17/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC

Media: Enduring Material
Activity Release Date: January 18, 2024
Activity Expiration Date: February 17, 2025
Time to Complete Activity: 60 minutes

Activity Description

Despite their established role in the treatment of HR+, HER2- metastatic breast cancer (MBC) and accumulating evidence supporting their adjuvant use in HR+, HER2- early breast cancer (EBC), questions still surround CDK4/6 inhibitors and their use. While these agents were historically thought to be largely similar and interchangeable, evolving data from clinical and translational studies have shown that CDK4/6 inhibitors are not the same. They have key differences in their chemical, biologic, pharmacologic, and clinical features and different toxicity profiles, despite all being orally bioavailable. Therefore, we must re-evaluate how we approach CDK4/6 inhibitors and integrate them into individualized treatment plans for patients throughout the disease continuum, as well as consider what that looks like in the real-world setting and how to make the most of them and their distinct properties in the frontline setting and beyond?

In this activity, based on a recent live virtual workshop, learners receive an in-depth, expert assessment of CDK4/6 inhibitors in HR+, HER2- EBC and MBC, which provides the foundation for case-based discussions and tool-based demonstrations of algorithmic decision aids designed to guide risk assessment, candidate selection for therapy, and the optimal delivery of treatment to reduce the risk of recurrence in individuals with HR+, HER2- EBC before transitioning to HR+, HER2- MBC to demonstrate patient evaluation, identify factors for prognostication, and model treatment planning, selection, and sequencing throughout the advance disease continuum. Additionally, the panel shares strategies to mitigate and manage common adverse reactions associated with CDK4/6 inhibitors to improve treatment adherence and persistence.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with early and metastatic breast cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients with HR+, HER2- EBC and MBC via thorough assessment of clinical, pathologic, genomic, and other relevant factors
  • Design individualized treatment protocols integrating CDK4/6 inhibitor therapy for patients with HR+, HER2- EBC and MBC based on the latest evidence, guidelines, and tumor/disease characteristics
  • Develop team-based strategies to achieve optimal treatment adherence/persistence and prevention/mitigation of AEs associated with different CDK4/6 inhibitors in the treatment of HR+, HER2- EBC and MBC

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Erika Hamilton, MD
Chair, Breast Executive Committee
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Erika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).
Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.; Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics; Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks Inc. (all paid to institution).

Faculty/Planner
Komal Jhaveri, MD, FACP
Patricia and James Cayne Chair for Junior Faculty
Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center/Evelyn H. Lauder Breast and Imaging Center
New York, New York

Komal Jhaveri, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.
Grant/Research Support from ADC Therapeutics SA; AstraZeneca; Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion Therapeutics; and Zymeworks Inc.

Faculty/Planner
Professor Stephen Johnston, MA, PhD
Professor of Breast Cancer Medicine & Head of Medical Oncology
Consultant Medical Oncologist & Head of The Breast Unit
The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research
Chelsea, London, United Kingdom

Professor Stephen Johnston, MA, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and Sanofi.
Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and Puma Biotechnology, Inc.
Speakers Bureau participant with AstraZeneca; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; and Pfizer.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-015-H01-P
Type of Activity: Application

Physician Assistants

AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/17/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

January 18, 2024
Meghan C. Thompson, MD/Catherine C. Coombs, MD
Credits: 1.0 CME / MOC / NCPD / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care

From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care

Start

 
 

From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care


 

Media: Enduring Material

    Activity Release Date: January 17, 2024

    Activity Expiration Date: February 16, 2025

    Time to Complete Activity: 60 minutes


 

Activity Description


 

Can you move from resistance to resilience with BTK inhibitors (BTKi) in relapsed/refractory chronic lymphocytic leukemia (CLL)? Learn how to overcome the well-recognized barriers—including therapeutic intolerance and disease progression—to effective sequential care by joining CLL experts in this case-based educational program. In this activity, developed in collaboration with CLL Society, the experts provide guidance on integrating new sequential BTKi options into everyday clinical practice and share patient scenarios designed to showcase skills that can help overcome medical challenges associated with continuous BTKi therapy over multiple lines of treatment. Don’t miss this opportunity to get back to resilient care with BTKi options in CLL!


 

Target Audience


 

This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, nurses, pharmacists, and other care team professionals involved in the management of patients with R/R CLL.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance

  •    
  • Implement best practices for capturing relevant prognostic factors, disease progression, and therapeutic intolerance to guide treatment planning with BTKi in R/R CLL

  •    
  • Formulate effective sequential treatment plans with BTKi strategies in CLL based on current evidence, prognostic information, and other patient- and disease-specific factors

  •    
  • Employ team-based approaches to address practical aspects of CLL care when using BTKi, including care coordination, formulary planning, patient education, dosing, and management of treatment-related AEs

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Co-Chair/Planner

    Meghan C. Thompson, MD

    Assistant Attending L1, Leukemia Service

    Memorial Sloan Kettering Cancer Center

    New York, New York


 

Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.

    Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.

 


 

Co-Chair/Planner

    Catherine C. Coombs, MD

    Associate Clinical Professor

    University of California, Irvine

    Orange, California


 

Catherine C. Coombs, MD, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AbbVie Inc.; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; MEI Pharma, Inc.; Mingsight Pharmaceuticals, Inc.; and Octapharma USA, Inc.

    Grant/Research Support from Lilly.

    Speaker for AbbVie Inc.; AstraZeneca; BeiGene, Inc.; and Genentech, Inc.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by an educational grant from Lilly.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.


 

Pharmacists


 

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

    Universal Activity Number: JA4008289-9999-24-011-H01-P

    Type of Activity: Application


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/16/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

   

    For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView



 
 

From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care


 

Media: Enduring Material

    Activity Release Date: January 17, 2024

    Activity Expiration Date: February 16, 2025

    Time to Complete Activity: 60 minutes


 

Activity Description


 

Can you move from resistance to resilience with BTK inhibitors (BTKi) in relapsed/refractory chronic lymphocytic leukemia (CLL)? Learn how to overcome the well-recognized barriers—including therapeutic intolerance and disease progression—to effective sequential care by joining CLL experts in this case-based educational program. In this activity, developed in collaboration with CLL Society, the experts provide guidance on integrating new sequential BTKi options into everyday clinical practice and share patient scenarios designed to showcase skills that can help overcome medical challenges associated with continuous BTKi therapy over multiple lines of treatment. Don’t miss this opportunity to get back to resilient care with BTKi options in CLL!


 

Target Audience


 

This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, nurses, pharmacists, and other care team professionals involved in the management of patients with R/R CLL.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance

  •    
  • Implement best practices for capturing relevant prognostic factors, disease progression, and therapeutic intolerance to guide treatment planning with BTKi in R/R CLL

  •    
  • Formulate effective sequential treatment plans with BTKi strategies in CLL based on current evidence, prognostic information, and other patient- and disease-specific factors

  •    
  • Employ team-based approaches to address practical aspects of CLL care when using BTKi, including care coordination, formulary planning, patient education, dosing, and management of treatment-related AEs

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Co-Chair/Planner

    Meghan C. Thompson, MD

    Assistant Attending L1, Leukemia Service

    Memorial Sloan Kettering Cancer Center

    New York, New York


 

Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.

    Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.

 


 

Co-Chair/Planner

    Catherine C. Coombs, MD

    Associate Clinical Professor

    University of California, Irvine

    Orange, California


 

Catherine C. Coombs, MD, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for AbbVie Inc.; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; MEI Pharma, Inc.; Mingsight Pharmaceuticals, Inc.; and Octapharma USA, Inc.

    Grant/Research Support from Lilly.

    Speaker for AbbVie Inc.; AstraZeneca; BeiGene, Inc.; and Genentech, Inc.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by an educational grant from Lilly.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.


 

Pharmacists


 

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

    Universal Activity Number: JA4008289-9999-24-011-H01-P

    Type of Activity: Application


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/16/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

   

    For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView


January 17, 2024
John L. Marshall, MD
Credits: 0.75 CME / MOC / CC / NCPD / CPE / AAPA / IPCE
PVI, PeerView Institute for Medical Education
Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team

Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team

Start

 
 

Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team


 

Media: Enduring Material

    Activity Release Date: January 12, 2024

    Activity Expiration Date: January 11, 2025

    Time to Complete Activity: 45 minutes


 

Activity Description


 

In this modern era of precision oncology, several therapies targeting pathways that contribute to metastatic colorectal cancer (mCRC) pathogenesis have emerged, including therapies targeting EGFR, VEGF, and the BRAF kinase. Selecting upfront and sequential treatment by considering patient- and tumor-related factors is key to informed shared decision-making and maximizing clinical benefit for patients. This activity features an expert overview of the significance of tumor sidedness in patients with mCRC, how to effectively utilize molecular testing to determine an appropriate course of treatment, and sequencing strategies across the mCRC spectrum.


 

Target Audience


 

This activity has been designed to meet the educational needs of oncologists, pathologists, radiologists, oncology nurses, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the care of patients with mCRC.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Implement tumor genotyping and evaluation of tumor sidedness at mCRC diagnosis based on current evidence, guideline recommendations, and an understanding of the mechanistic rationale

  •    
  • Formulate personalized mCRC treatment plans with targeted therapies that are driven by molecular findings and primary tumor localization and supported by the latest evidence and guideline recommendations using a team-based approach

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Chair/Planner

    John L. Marshall, MD

    Director, The Ruesch Center for the Cure of GI Cancers

    Frederick P. Smith Endowed Chair

    Chief Medical Officer

    Lombardi Comprehensive Cancer Center

    Georgetown University Medical Center

    Washington, District of Columbia


 

John L. Marshall, MD, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Arcos; AstraZeneca; Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose; Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical Company Limited; and Zcurex.

    Grant/Research Support from Arcos; AstraZeneca; Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose; Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical Company Limited; and Zcurex.

    Other Financial or Material Support Executive role for Indivumed GmbH.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by an educational grant from Lilly.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Continuing Certification Statement


 
   
     
       
       
     
   
 
ABPath The activity titled “Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team” has been registered to offer 0.75 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.


 

Pharmacists


 

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    Universal Activity Number: JA4008289-0000-23-066-H01-P

    Type of Activity: Application


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 1/11/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

   

    For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/CC/NCPD/CPE/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView



 
 

Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team


 

Media: Enduring Material

    Activity Release Date: January 12, 2024

    Activity Expiration Date: January 11, 2025

    Time to Complete Activity: 45 minutes


 

Activity Description


 

In this modern era of precision oncology, several therapies targeting pathways that contribute to metastatic colorectal cancer (mCRC) pathogenesis have emerged, including therapies targeting EGFR, VEGF, and the BRAF kinase. Selecting upfront and sequential treatment by considering patient- and tumor-related factors is key to informed shared decision-making and maximizing clinical benefit for patients. This activity features an expert overview of the significance of tumor sidedness in patients with mCRC, how to effectively utilize molecular testing to determine an appropriate course of treatment, and sequencing strategies across the mCRC spectrum.


 

Target Audience


 

This activity has been designed to meet the educational needs of oncologists, pathologists, radiologists, oncology nurses, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the care of patients with mCRC.


 

Educational Objectives


 

Upon completion of this activity, participants should be better able to:


 

  •    
  • Implement tumor genotyping and evaluation of tumor sidedness at mCRC diagnosis based on current evidence, guideline recommendations, and an understanding of the mechanistic rationale

  •    
  • Formulate personalized mCRC treatment plans with targeted therapies that are driven by molecular findings and primary tumor localization and supported by the latest evidence and guideline recommendations using a team-based approach

  •  

 

Disclosure Policy


 

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


 

Faculty/Planner Disclosures


 

Chair/Planner

    John L. Marshall, MD

    Director, The Ruesch Center for the Cure of GI Cancers

    Frederick P. Smith Endowed Chair

    Chief Medical Officer

    Lombardi Comprehensive Cancer Center

    Georgetown University Medical Center

    Washington, District of Columbia


 

John L. Marshall, MD, has a financial interest/relationship or affiliation in the form of:

    Consultant and/or Advisor for Arcos; AstraZeneca; Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose; Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical Company Limited; and Zcurex.

    Grant/Research Support from Arcos; AstraZeneca; Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose; Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical Company Limited; and Zcurex.

    Other Financial or Material Support Executive role for Indivumed GmbH.

 


 

Planning Committee and Reviewer Disclosures


 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.


 

Accreditation, Support, and Credit


    
 
   
     
       
       
     
   
 
JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Support


 

This activity is supported by an educational grant from Lilly.


 

Physicians


 

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).


 

MOC Statement


 
   
     
       
       
     
   
 
MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points  and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Continuing Certification Statement


 
   
     
       
       
     
   
 
ABPath The activity titled “Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team” has been registered to offer 0.75 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit.

 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).


 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


 

Nurses


 

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.


 

Pharmacists


 

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    Universal Activity Number: JA4008289-0000-23-066-H01-P

    Type of Activity: Application


 

Physician Assistants


 
   
     
       
       
     
   
 
AAPA PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 1/11/2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement


 
   
     
       
       
     
   
 
IPCE This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Method of Participation


 

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

   

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

   

    If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

   

    For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

   

    For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.


 

Disclosure of Unlabeled Use


 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

About This CME/MOC/CC/NCPD/CPE/AAPA/IPCE Activity


 

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.


 

Copyright © 2000-2024, PeerView


January 12, 2024

Pages